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Abstract 
 
 
Incidence and Regulatory Implications of Single Nucleotide 
Polymorphisms among Established Ovarian Cancer Genes 
 
K. Ramdayal 
 
Magister Scientiae in Bioinformatics, Thesis,  
Department of Biotechnology, University of the Western Cape 
 
 
OVARIAN cancer research focuses on answering important questions related to the 
disease, determining whether new approaches are feasible to contribute towards 
improving current treatments or discovering new ones. This study focused on the 
transcriptional regulation of genes that have been implicated in ovarian cancer, based 
on the occurrences of single nucleotide polymorphisms (SNPs) within transcription 
factor binding sites (TFBSs). Through the application of several in silico tools, 
databases and custom programs, this research aimed to contribute toward the 
identification of potentially bio-medically important genes or SNPs for pre-diagnosis 
and subsequent treatment planning of ovarian cancer. A total of 379 candidate genes 
that have been experimentally associated with ovarian cancer were analyzed. This led 
to the identification of 121 SNPs that were found to coincide with putative TFBSs 
potentially influencing a total of 57 transcription factors that would normally bind to 
these TFBSs. These SNPs with potential phenotypic effect were then evaluated 
among several population groups, defined by the International HapMap consortium 
resulting in the identification of three SNPs present in five or more of the eleven 
population groups that have been sampled.  
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After analysis of the allele frequencies of each of the three SNPs and comparison to 
the ancestral alleles of each, SNPs rs12928665, rs20577 and rs4150842, present on 
genes CIITA, TNFRSF10A and E2F5, were observed as the only three SNPs that 
potentially influence the binding of the CDP, CP2/LBP-1c/LSF and/or C/EBP 
transcription factors at their putative transcription factor binding sites. These SNPs 
may be considered as potential diagnostic markers for the prognosis of ovarian cancer 
in high-risk women from specific population groups.  
 
Furthermore, this study has highlighted a computational approach for the 
identification of SNPs coinciding with TFBSs that may play a role in the regulatory 
mechanisms encoded for by cancer-associated genes. This approach may be applied 
to the elucidation of SNPs influencing TFBSs in other complex diseases given the 
time and system requirements.  
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Preface 
 
 
The Incidence and regulatory implications of single nucleotide polymorphisms among 
established ovarian cancer genes was undertaken at the South African National 
Bioinformatics Institute (SANBI) situated at the University of the Western Cape 
(UWC) between November 2007 and May 2009 under the supervision of Prof. Heikki 
Lehväslaiho and Prof. Vladimir B. Bajic. The Microsoft Word (.doc) or Portable 
Document Format (.pdf) versions of this work can be requested from the author at the 
following address: kramdayal@gmail.com.  
 
The focus of this study was to provide an insight into the use of SNPs as potential 
biomarkers for ovarian cancer and the possibility of using this information in the early 
detection and/or treatment planning of the disease. The thesis consists of two major 
parts.  
 
The first part comprises of the identification of SNPs having potential phenotypic 
effect that coincide with TFBSs within genes that have been implicated (i.e. 
experimentally proven) in ovarian cancer. The second part consists of the exploration 
of these possible functional SNPs (identified in part one) that occur in several 
population groups defined by the International HapMap consortium, qualifying them 
as possible diagnostic markers that may be applied to the early detection of ovarian 
cancer.  
 
 
 
 
 
 
 
 
September 2009 Kavisha Ramdayal 
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CHAPTER 1 
 
 
Introduction 
 
 
OVARIAN cancer affects more than 200,000 women around the world every year 
(Helm et al., 2009). It has the highest mortality rate of all cancers of the female 
reproductive system and is the fifth leading cause of cancer-related death among 
women in the USA alone (U.S. National Institutes of Health, 2001). Due to the lack of 
early symptoms and proven ovarian cancer screening tests, ovarian cancer is often 
diagnosed at an advanced stage when the cancer has spread beyond the ovary (U.S. 
National Institutes of Health, 2001 & Helm et al., 2009). Although recent scientific 
discoveries have led to new insights into cancer prevention, detection and treatment in 
the past, gynecological cancers are still claiming the lives of hundreds of thousands of 
women (U.S. National Institutes of Health, 2001). 
 
 
1.1 Cancer 
 
“Cancer is an extremely complex, heterogeneous disease, which displays a degree of 
complexity at the physiological, tissue and cellular levels”, (Wang et al., 2007). 
Cancers arise from a loss of normal growth control and can originate almost anywhere 
in the body in the form of carcinomas, sarcomas, lymphomas or leukemias, with the 
most common being carcinomas that arise from cells covering the external or internal 
surfaces of the body, e.g. lung, breast and colon cancers (U.S. National Institutes of 
Health, 2001 & Bupa, 2007).  
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Figure 1.1 Malignant versus benign tumors (U.S. 
National Institutes of Health, 2001). Malignant 
tumors are a more serious health problem than 
the benign tumors, as these cancer cells can 
spread to distant parts of the body and can 
therefore be potentially life threatening (U.S. 
National Institutes of Health, 2001 & The New 
York Times, 2009).  
Cancer occurs in the body in the 
form of tumors that are classified 
as being either benign or 
malignant, depending on whether 
or not abnormal cell growth can 
spread by invasion or metastasis 
(Bupa, 2007). Benign tumors are 
tumors that cannot spread by 
invasion or metastasis and can 
only grow locally whereas 
malignant tumors are capable of 
spreading through invasion and 
metastasis as described in Figure 
1.1 (U.S. National Institutes of 
Health, 2001).  
 
There are over 200 different kinds of cancer, named according to the part of the body 
where the cancer or tumor originates (e.g. brain, breast, cervix, colon, lung, ovary, 
prostate, skin, etc.) (Cancer Association of South Africa, 2008). Ovarian cancer falls 
within the category of gynaecological cancers, as it begins in the reproductive system 
of women with the most common types of gynaecologic malignancies being cervical, 
ovarian, and endometrial (uterus) cancer (Cancer Research UK, 2008 & CancerIndex, 
2003).  
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1.2 Ovarian Cancer  
 
Ovarian cancer develops within the cells of one or both of the ovaries present in the 
uterus of a women, with 90% of these beginning in the cells that cover the outer 
surface of the ovary (ecancermedia, 2008).  
 
 
Figure 1.2 Healthy ovary compared to cancerous ovary (HealthSquare.com, 2009). Most 
often than not ovarian cancer develops without any troubling symptoms, leading to the 
tumor developing to a stage when it is eventually detected as a mass after physical 
examination of the pelvic area (HealthSquare.com, 2009). 
 
Due to the lack of early detection strategies, most patients with ovarian cancer are 
diagnosed when the disease has progressed to an advanced stage, when there is only a 
5-year overall survival rate of approximately 20% (Coukos et al., 2008).  
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1.2.1 Stages of Ovarian Cancer 
 
The staging of cancer is a crucial factor to consider in the development of a treatment 
regimen for each patient to improve the treatment outcome (National Ovarian Cancer 
Coalition, 2009). Ovarian cancer is divided into four major stages that are determined 
by the progression of the disease within the body as described by Figure 1.3 below.  
 
 
Figure 1.3 Ovarian cancer stages of disease 
progression (National Ovarian Cancer 
Coalition, 2009). As the disease progresses 
from Stage 1 to 4, survival rates have been 
shown to decline dramatically from an initial 
±90% survival rate at Stage 1 to a less than 
5% survival rate at Stage 4 (National Ovarian 
Cancer Coalition, 2009). 
Stage 1: One or both ovaries is/are 
cancerous. 
Stage 2: One or both ovaries is/are 
cancerous and the disease has spread 
to the uterus, fallopian tubes or other 
parts in the pelvic area of the body. 
Stage 3: One or both ovaries is/are 
cancerous and the disease has spread 
to the lymph nodes or other parts of 
the body inside the abdomen. 
Stage 4: One or both ovaries is/are 
cancerous and the disease has spread 
outside the abdomen and/or to the 
liver (National Ovarian Cancer 
Coalition, 2009).  
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1.2.2 Types of Ovarian Cancer 
 
There are approximately 30 known types and subtypes of ovarian cancer 
malignancies, each with its own biological characteristics that may be grouped into 
three major categories (Table 1.1) according to the kind of cells from which they were 
formed (OncologyChannel, 2009). 
 
Table 1.1 Three major types of ovarian cancer. Although some tumors that are found 
adjacent to ovarian tissues are viewed and treated as ovarian cancer (e.g. cancer of the 
membrane lining the walls of the pelvic cavity next to the ovaries) the three major 
categories include the following (OncologyChannel, 2009): 
Type Origin 
Epithelial tumors  Cells that line or cover the ovaries 
Germ cell tumors Cells that develop into eggs within the ovaries 
Sex cord-stromal cell tumors Connective cells that hold the ovaries together and 
produce hormones 
 
Epithelial tumors account for about 90% of all ovarian cancers, occurring in women 
between the ages of 30 and 80, and can be further subdivided into serous, 
endometrioid, mucinous and clear cell tumors (OncologyChannel, 2009). From all the 
diagnosed cases of these tumors, approximately 50% of serous tumors, 80% of 
endometrioid tumors, 5% of mucinous tumors and nearly all clear cell tumors are 
found to be malignant (OncologyChannel, 2009). Unlike epithelial tumors however, 
60-70% of patients with germ cell tumors are diagnosed at stage 1 of the disease 
(Figure 1.3), whereas 75% of epithelial ovarian cancers are diagnosed when the 
disease has already progressed to stages 3 or 4 (OncologyChannel, 2009). 
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1.2.3 Risk Factors  
 
“The overall lifetime risk of any woman developing ovarian cancer is low, however 
certain factors can increase that risk by 11% to 65%”, (Anderson, 2009). The use of 
hormone-replacement therapy (HRT) may be one of the factors that contributes 
towards the development of ovarian cancer, as indicated by Blagden et al. (2008), 
who estimated this to be the cause of an additional 1300 cases of ovarian cancers 
since 1991. Another contributing factor identified by the Million Women Study, to be 
a cause of ovarian cancer, among a number of other tumors, was obesity (Blagden et 
al., 2008).  
 
Unlike other cancers that arise from a range of origins, mostly environmentally or 
lifestyle linked (Hertel et al., 2008), the strongest risk factor for ovarian cancer comes 
from family history as a result of inherited cancer susceptibility genes such as BRCA1 
or BRCA2 (Anderson, 2009; Blagden et al., 2008; King et al., 2003a). King et al. 
(2003a) found that risks (related to women that inherited mutations in the tumor 
suppressor genes BRCA1 and BRCA2) appeared to be increasing with time, and found 
lifetime risks of ovarian cancer amounting to 54% for BRCA1 and 23% for BRCA2 
mutation carriers (King et al., 2003a). 
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Table 1.2 Factors responsible for an increased risk for ovarian cancer. Other factors that 
have been reported to cause an increased risk for ovarian cancer include the following 
(Anderson, 2009; Bupa, 2007 & ecancermedia, 2008): 
 
Factor Description 
 
Age 
 
Ovarian cancers occur most often after menopause, with 
50% of these cases found in women above the age of 65 
 
Children 
 
There are slightly increased risks for women that do not 
have children or had their first child after the age of 30 
 
Diet 
 
 
 
Although obesity has been described as a contributing factor 
by Blagden et al., (2008), some studies suggest that even a 
high fat diet may increase ovarian cancer risk 
 
Menstrual Cycles 
 
Women who started having periods early (before 12 years 
old) or those who go through menopause after the age of 50 
have a slightly increased risk for ovarian cancer  
 
Fertility Drugs 
 
Prolonged use of fertility drugs may increase the risk for 
ovarian cancer, however infertility also increases the risk, 
even without the use of fertility drugs 
 
Genetics 
 
In addition to inherited gene mutations of the BRCA1 and 
BRCA2 genes, an inherited disease known as Hereditary 
Nonpolyposis Colon Cancer (HNPCC) increases the risk for 
ovarian cancer 
 
Breast Cancer 
 
Women that have had breast cancer have a higher risk for 
ovarian cancer 
 
Estrogen-Replacement 
Therapy (ERT) 
 
Long-term use (10 or more years) of ERT after menopause 
has been shown by most studies to slightly increase the risk 
for ovarian cancer 
 
Carcinogen Exposure 
 
These include asbestos, benzene and radioactive materials 
 
Weak Immune System 
 
This may be the result of medicines that suppress the 
immune system, e.g. high doses of radiation in the case of 
radiotherapy that may be employed to target another cancer 
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1.2.4 Symptoms 
 
Symptoms are usually the result of the cancer growing and causing pressure or pain as 
a result and may include any of the following attributes (Bupa, 2007 & ecancermedia, 
2008): 
 
(1) Swelling of the stomach 
(2) Abdominal pain 
(3) Digestive problems (e.g. indigestion, constipation, appetite loss, etc.) 
(4) Unexpected weight gain/loss 
(5) Frequent need to urinate 
(6) Unusual vaginal bleeding 
(7) Back or leg pain 
(8) Bowel or bladder changes 
 
However, although there are a few identifiable symptoms of early-stage ovarian 
cancer, these are thought to be subtle or absent, making diagnosis difficult and 
patients reluctant to seek help (Anderson, 2009 & Bupa, 2007). 
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1.2.5 Diagnosis 
Early stages of ovarian cancer are difficult to detect typically because the disease has 
very vague signs or symptoms, many of which could easily be mistaken or not 
considered as an indication of ovarian cancer (Anderson, 2009).  
 
Table 1.3 Existing tests to confirm the presence of ovarian cancer. Traditionally ovarian 
cancer diagnosis techniques include the following tests or procedures (Bupa, 2007; 
ecancermedia, 2009; HealthSquare.com, 2009 & National Ovarian Cancer Coalition, 
2009):  
 
Technique Description 
 
Imaging studies  
 
 
Will detect if there is a mass present in the pelvis, but 
cannot convey if it is cancer 
 
Ultrasound 
 
Uses sound waves to create an image on a video screen, 
distinguishing between tumors and normal tissue based on 
their varying reflection of sound waves 
 
Computed Tomography 
(CT) scan 
 
Uses a computer and an x-ray beam to take a series of 
pictures of the body from many angles and then combines 
them into a detailed image on the computer 
 
Magnetic Resonance 
Imaging (MRI) 
 
The MRI displays a cross-sectional picture of the body using 
radio waves and strong magnets instead of x-rays 
 
CA125 Assay 
 
CA125 is a protein that is a tumor marker and is measured 
via a blood sample. Elevated levels of CA125 are 
associated with the presence of ovarian cancer, but have 
been shown to produce numerous false positive results. 
 
Laparoscopy 
 
Entails the insertion of a thin light tube into the lower 
abdomen via a small incision and permits the doctor to 
examine the ovaries and other pelvic organs 
 
 
The prospect of reducing ovarian cancer mortality rates through earlier diagnosis and 
treatment is a high priority, but available screening approaches such as those 
mentioned in Table 1.3 often fail to detect this disease at an early stage and/or can 
sometimes lead to unnecessary surgery (Coukos et al., 2008). 
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1.2.6 Treatment 
 
Ovarian cancer very often causes few symptoms until it has metastasized within the 
peritoneal cavity at which time the chance of cure is significantly reduced (Helm et 
al., 2009). Even though ovarian cancer therapy has improved, the 5-year survival 
rates for stages
 
I, II, III and IV are 74, 58, 30 and 19%, respectively (Steele et al., 
1994). Depending on the size, location, type and progression of the cancer, the most 
common types of treatment are surgery, chemotherapy and radiotherapy, or a 
combination of these treatments in varying degrees (Bupa, 2007 & ecancermedia, 
2008). 
 
1.3 Genetic Variation 
 
DNA variations between individuals can be an indication of predisposition to disease 
or affect the degree of response to treatment (Stepanova et al., 2006). Identification of 
functional genetic variation associated with increased susceptibility to complex 
diseases can elucidate genes and underlying biochemical mechanisms linked to 
disease onset or progression (Malin et al., 2008). 
 
 
Figure 1.4 Illustration of a single 
nucleotide polymorphism between 
two DNA strands (GnpSNP, 2009).  
Genetic differences occur in various ways, most 
with no medical consequences to our health, 
such as inheriting our mother’s hair or father’s 
eyes, whereas others have more significant 
effects, affecting protein activity or gene 
expression rendering some more genetically 
susceptible to diseases than others (Roche, 
2008; U.S. National Institutes of Health, 2001; 
Tebbutt et al., 2007). SNP detection is one of 
the most powerful tools in the search for disease 
susceptibility genes and drug response-
determining genes (Conde et al., 2006).  
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In contrast to more mutable markers such as microsatellites, SNPs have a low rate of 
recurrent mutation, making them stable indicators of human history (Sachidanandam 
et al., 2001). In a study by Chowdhury et al. (2006), SNPs were identified within a 
region ±1200bp upstream and 1300bp downstream of the transcription start site (TSS) 
of the peptidase inhibitor 3 gene.  
 
TFBSs were then detected from related and unrelated sites and SNPs genotyped from 
them (Chowdhury et al., 2006). Results indicated a differential binding of 
transcription factors, providing evidence of functional promoter variants existing 
within genes (Chowdhury et al., 2006). TFs acting upon these TFBSs containing 
genetic polymorphisms (i.e. SNPs) have also been shown to have diverse effects 
within the cell, with various indicators as by-products. An example of this is the USF-
1 TF, which is associated with an increased adipocyte lipolysis (Hoffstedt et al., 
2005). Hoffstedt et al. (2005) describe the implications of an increased mRNA level 
of protein kinase A (a post-receptor enzyme) that highlighted the viability for 
monitoring ‘SNP by-products’ in the cell.   
 
Another example of the effect of mutations within a TF binding domain, described by 
Sakazume et al. (2007) explains the effect of mutations affecting regulatory elements 
on the PITX3 gene (responsible for normal eye development in vertebrates). The 
study focused on a subset of human patients wherein PITX3 mutations demonstrated 
corneal anomalies with cataract/lens defects present in all cases (Sakazume et al., 
2007). 
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1.4 Regulatory Genomics 
 
Biological diversity is governed by the biochemical processes that constitute gene 
regulation and is an important mechanism for the regulation of gene expression 
(Wasserman et al., 2004 & Alkema et al., 2004). Transcription constitutes this first 
step in the expression of genes and is central to the regulatory mechanisms within any 
biological cell (Wasserman et al., 2004). Transcription regulation is shaped by the 
interactions between transcription factors (TFs) that bind to cis-regulatory elements in 
DNA and additional trans-acting proteins that aid/control the rate of transcription 
within each individual gene (Wasserman et al., 2004). Transcriptional gene regulation 
is dependent on the “sequence-specific binding of TFs to regulatory regions of genes, 
thereby repressing or activating transcription”, (Harbison et al., 2004 & Alkema et al., 
2004).  
 
A transcription factor; sometimes referred to as a “sequence-specific DNA binding 
factor”, is a protein that binds to specific parts of DNA through its recognition of 
DNA binding domains and enables/disables the system that controls the transcription 
of DNA to RNA (Yang, 1998). The DNA binding domain (DBD) as described by 
Aranda et al. (2001) is composed of two zinc finger proteins made up of 60-70 amino 
acids, the first of which includes a region called the P box that is able to recognize the 
core DNA motifs (Aranda et al., 2001). The second zinc finger protein has a D box 
region that is responsible for dimerisation and allows rotation of the DNA binding 
domain (Aranda et al., 2001 & Robinson-Rechavi et al., 2003).  
 
Transcription factors play an important role in genetic regulation via the transcription 
process and have become a great research focus area as they make it possible to 
alter/impair physiological processes in a given disease (Genfit, 2009 & Janga, 2007). 
Transcription is sometimes performed solely by transcription factors or through the 
use of other proteins in complex by increasing or decreasing the presence of RNA 
polymerase (Berg et al., 2004).  
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Most genes in the genome are controlled by a combination of “trans-acting factors”, 
i.e. many TFs that bind cooperatively to their associated DNA sequences and 
subsequently recruit transcriptional cofactors (Hobert, 2008). 
 
 
Figure 1.5 Cellular regulatory factors responsible for the transcription of RNA from DNA. 
In cells, transcription factors (TFs) are responsible for the control of tissue functionality 
and gene expression, depending on if they are activated, genes will be switched on (up-
regulated) and others switched off (down-regulated) (Genfit, 2009 & Goffart et al., 2003). 
TFs (1) bind to specific DNA consensus elements in the promoter region of DNA 
sequences and activate transcription by stabilizing the polymerase initiation complex 
(Goffart et al., 2003). Other regulatory factors, such as protein complexes (2), co-
activators (3), ligands (4) regulatory DNA sequences (5) and enhancers (6) may 
additionally work co-operatively in the mediation or enhancement of transcription 
regulation (Goffart et al., 2003).  
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Numerous computational methods have been derived for the discovery of cis-
regulatory elements including the use of “correlation with expression” techniques as 
described by Bussemaker et al. (2001). These researchers use a method of clustering 
genes based on their expression profiles, thus uncovering groups of genes that co-vary 
based on shared cis-regulatory regions. Bussemaker et al. (2001) were able to uncover 
patterns of combinatorial transcriptional control through analysis of mRNA levels and 
found that certain motifs were correlated to expression of transcription factor binding 
sites (TFBSs) in the 600bp upstream region of the transcription start site.  
 
A few years ago, methods for the identification of TFBSs incorporated the use of 
weight matrices containing scores for all possible bases at each position in a binding 
site (Benos et al., 2002). True binding sites score higher than sites that do not bind 
transcription factors. Benos et al. (2002) proposed a model where they measured the 
binding affinities of proteins to DNA. Despite the fact that their model did not fit the 
data perfectly, in most cases it provided a very good approximation for the discovery 
and prediction of genomic DNA binding sites.  
 
Hannenhalli et al. (2002) introduced the concept of modules, present in a few hundred 
base pairs proximal to the gene. These various modules work together in the 
regulating of gene expression to constitute a promoter module (Hannenhalli et al., 
2002). The authors highlight the need for analyzing the transcription factors that bind 
to these regions and hypothesized that the transcription factors responsible for activity 
within the promoter sites are likely to be part of a transcriptional module on the 
human genome sequence (Hannenhalli et al., 2002). McNutt et al. (2005), who have 
shown that TFBS composition is non-randomly distributed between gene promoters 
in a manner that defines gene class function, later confirmed the validity of this 
hypothesis.  
 
 
 
 
 
 
 
 
 
 
 15 
Harbison et al. (2004) demonstrated eukaryotic transcription via their study of the 
yeast cell. Regulatory binding sites within the yeast cell were clustered between 100 – 
500bp upstream of the coding region and not randomly distributed (Harbison et al., 
2004). They also observed four types of promoters, which were classified according 
to the architecture of the binding sites in terms of their organization (Harbison et al., 
2004). Pavesi et al. (2004) suggested that the problem associated with the data models 
was that many are based on the analysis of yeast genes, who inherently have a short 
regulatory region (<1000bp) whereas human genes have longer and more complex 
regulatory modules that include enhancers and silencers (Pavesi et al., 2004).  
 
Alternatively, in an investigation of prokaryotic gene expression, Elf et al. (2007) 
observed the kinetics of binding and dissociation of the repressor in response to 
metabolic signals. Moreover, they managed to characterize the nonspecific binding to 
DNA, observing the facilitated diffusion of the repressor along the DNA strand in 
their search for an ‘operator’ (Elf et al., 2007). Although this study was performed in 
prokaryotes, the principles or dynamics of single molecule detection are essential in 
the investigation of how a transcription factor molecule identifies and binds to 
specific binding sites along the DNA strand. These results corroborate with those of 
Fessele et al. (2002) who showed that organizational features of sequence promoter 
regions contain information about the functional context of gene expression. 
  
Berg et al. (2004) have also contributed to the area of TFBS identification by showing 
that the selection for transcription factor binding generally leads to specific 
correlations between nucleotide frequencies at different positions of a binding site. 
Different sites for the same transcription factor can differ by about 20-30% of the 
bases relevant for binding, making them difficult to identify (Berg et al., 2004).  
 
Berg et al. (2004) go on to describe binding co-operativity, wherein simultaneous 
binding at two nearby sites is energetically favored, as it requires lesser energy and 
this action may be related to various functions. The promoter region is the regulatory 
region of all DNA sequences, located upstream of a gene, it provides a control point 
for regulated gene transcription and is typically a few thousand base pairs long 
containing many different transcription factor binding sites (Berg et al., 2004).  
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Other studies have demonstrated the need for TFBS profile libraries to be extensively 
used to identify regulatory elements in DNA sequences (Kielbasa et al., 2005). 
Findings by Kielbasa et al. (2005) reveal two measuring yardsticks that compliment 
each other; i.e.: X
2
 distances between 
*
PFMs and correlation coefficients between 
position weight matrix (PWM) scores (Su et al., 2006). This is in contrast to the 
representations of King et al. (2003b), who attempted to identify TFBSs using a 
collection of aligned known binding sites. King et al. (2003b) discovered that TFBSs 
are strongly conserved and tend to occur in clusters. Elnitski et al. (2006) corroborate 
this idea by reiterating the usefulness of representing information within regulatory 
sites in the form of position weight matrices (PWMs) or position-specific scoring 
matrices (PSSMs) which incorporate pattern variability by recording nucleotide 
frequencies at each site or by assigning penalties to nucleotides that should not be 
within a factor binding site.  
 
Identifying TFBSs in vitro is in itself a problematic task, as these sites are miniscule 
in size and methods that scan sequences for matches to a consensus-binding site 
produce high false positive rates due to the low specificity (Alkema et al., 2004). 
Hestand et al. (2008) have been one of the many groups to create a computational 
method able to reduce the identification of false positives in the 
identification/prediction of TFBSs.  
 
Algorithmic approaches that have been developed for de novo pattern detection that 
search for recurring or overrepresented patterns in DNA include Hidden Markov 
Models, Gibbs sampling, greedy alignment algorithms (e.g. CONSENSUS), 
expectation-maximization (e.g. MEME), probabilistic mixture modeling (e.g. 
NestedMica) and exhaustive enumeration methods (Elnitski et al., 2006). 
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In recent years, various computational models have been designed to understand gene 
regulatory networks in response to various stimuli. Hermsen et al. (2006) 
demonstrated one such model, wherein a computer model of transcriptional regulation 
that was allowed to evolve by mutation. The resulting cis-regulatory regions were 
thereafter observed to have tandem and often overlapping binding sites to which TFs 
could bind cooperatively and competitively, enabling the efficient integration of 
signals (Hermsen et al., 2006). The emergence of phylogenetic footprinting to 
identify binding sites has also been another novel approach to the study of 
orthologous genes, for the analysis of common regulatory mechanisms even though 
regulatory sequences have diverged to render alignment non-existent as regulatory 
CRM (cis-regulatory module) models are another offset of functional binding site 
predictive algorithms, which are showing increased improvement in prediction as they 
become more optimized (Wasserman et al., 2004).  
 
Techniques to identify functional transcription factor binding sites in mammals, both 
experimentally and computationally (i.e. in silico, in vitro and in vivo), have also been 
described by Elnitski et al. (2006). Experimental techniques are methods that identify 
regulatory elements by indirectly measuring transcription factor/DNA interactions 
whereas computational analysis require data sets and are based on either pattern 
matching or pattern detection that make use of prior knowledge of all characterized 
DNA binding sites for a given transcription factor (Elnitski et al., 2006).   
 
In bacterial genetics, transcription factors (TFs) have been hypothesized as a major 
contributor to an organism’s response to various external stimuli and a large amount 
of ongoing work has been focused on predicting the set of transcription factors 
responsible for gene regulation (Yang et al., 2007). Most current methods attempt to 
identify possible binding sites from a genomic sequence but predicting transcription 
factors from these sequences often results in the inclusion of numerous false positives 
(Yang et al., 2007). Little is known about their functional roles, expression dynamics 
and evolutionary scenarios (Janga, 2007). Relationships between homologous genes 
and structures imply correlations of evolutionary changes at different levels of 
biological organization and data from a variety of organisms have provided 
significant insight into the evolutionary relationship between genotype and phenotype 
(Wray, 2007).  
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Gene expression is extremely complex, but each discovery in the myriads of 
molecular interactions provides a building block for deciphering the regulatory 
mechanisms of each cell. According to Abnizova et al. (2007), not very much is 
known about the regulation of transcription in eukaryotes. More specifically, very 
little is known about the TFBSs and the interacting protein patterns. The authors 
presented a theory claiming that numerous transcription factors work together in a 
combinatorial manner to enable cells to respond to various signals/stimuli consisting 
of either a development or environmental nature. Abnizova et al. (2007) considered 
gene regulatory networks as being the key to understanding transcriptional regulatory 
mechanisms in eukaryotes. They motivate for the use of various TFBS motif-search 
algorithms to understand the enormous amounts of variant information encoded in 
genomic data. Furthermore they emphasize the use of algorithms to search for 
combinations of TFBS that are enriched in sets of co-regulated genes (Abnizova et 
al., 2007). These tools will improve TFBS predictions and improve our understanding 
of gene regulatory network (GRN) construction (Stormo, 2000).  
 
More recently, an important census study by Vaquerizas et al. (2009) has provided 
clues as to how transcription factors (TFs) may operate. These researchers express the 
lack of a reliable data set of TFs in the human genome and the problems associated 
with false predictions created through in silico studies. They were however, able to 
indicate where TFs are present with an analysis of chromosomal clusters of genes in 
relation to their evolutionary histories providing insights into how these regulators 
function.  
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1.5 SNPs & Complex Diseases 
Complex diseases are usually those attributed to a combination of environmental 
factors and genes that result in a phenotypic change (Lowe, 2001). Screening efforts 
to identify genes for complex diseases, such as ovarian cancer are complicated when 
considering the risk for developing this disease depends on a particular combination of 
susceptibility alleles in many linked or unlinked genes (Lowe, 2001). Despite these 
challenges there have been several reports describing the identification of genes that 
have been linked to complex diseases in some or other form. With the vast amounts of 
expression data generated in the past few years, researchers have been finely mapping 
the the expression levels of many genes, searching for the presence of single 
nucleotide variations that act as possible triggers in the development of complex 
diseases (Prokunina et al., 2004). Linkage analysis provides researchers with this 
crucial information about where in the genome these genetic variations are located 
and have been “highly successful for many rare single-gene disorders”, (Gibbs et al., 
2003 & Prokunina et al., 2004). The International HapMap Project has provided 
researchers with the foundation to do exactly this, through their provision of a freely 
available map of common patterns of DNA sequence variation within the human 
genome (Gibbs et al., 2003). 
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1.6 The International HapMap Project 
 
Designed to create a public genome-wide database of patterns of common sequence 
variation, the International HapMap Project emerged as a logical step in the 
characterization of human genomic variation (Manolio et al., 2008). Aimed toward 
genetic studies of human health and disease, the HapMap Project has introduced a 
new paradigm of research in the form of genome-wide association studies (Manolio et 
al., 2008).  
 
The project collected and analyzed DNA samples from a multitude of population 
groups, initially of African, Asian and European descent, and identified SNPs within 
these samples in search of haplotypes with frequencies of 5% or higher within each 
population group (Nomikos, 2006). The goal of this project ultimately is to identify 
regions containing disease alleles or alleles that predispose individuals to a type of 
disease (i.e. from a particular environmental factor or medication) (Nomikos, 2006). 
 
 
Figure 1.6 The International !HapMap Project main page. Initially launched in 2002 as 
an international effort to identify and catalog genetic similarities and differences, the 
HapMap project was initiated to identify how these genetic variations are distributed 
among people within various population groups (Nomikos, 2006).  
 
                                                
! http://hapmap.org/ 
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The HapMap project has enabled the functional investigation and comparison of 
candidate disease genes across several population groups, providing researchers with 
new insights into the evolutionary pressures on the human genome (Manolio et al., 
2008). Moreover, it has led to the vast improvement of methodologies capable of 
reliably estimating genotypes of SNPs that have not been ‘typed’ on existing 
genotyping platforms, based on information from typed SNPs (Manolio et al., 2008). 
 
1.7 Using SNPs in Drug Development 
 
The application of genetic variation data will enable scientists to discover sequence 
variants that affect common diseases, or facilitate the development of diagnostic tools 
that will enhance our ability to choose specific drug targets for therapeutic 
intervention (Gibbs et al., 2003). Single base variations in the human genome may 
increase the risk of developing a disease or lower the likelihood of response to a 
specific medicine (Roche, 2008 & Ramaswamy et al., 2003). The use of SNP markers 
in the evaluation of DNA samples and analysis of clinical data regarding drug safety 
and efficacy will make it possible to correlate patient response to medication with 
specific genetic profiles (GalaxoSmithKline, 2006).  
 
Understanding how SNPs are involved in the susceptibility or resistance to a disease, 
or in the efficacy/toxicity of drugs is a major goal and the overall aim of 
pharmacogenomics (Xie et al., 2005). Combining this knowledge with that of the 
molecular pathways involved in specific diseases and the role that SNPs have to play 
in these pathways, will provide researchers with an understanding of new potential 
drug targets, enabling improved intervention and more precise treatment strategies 
(Frazer et al., 2009). 
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CHAPTER 2 
 
 
Research Motivation 
 
 
THIS year hundreds of thousands of women will be told that they have ovarian cancer. 
Last year 15520 women died from the disease of the 21650 affected in the United 
States alone (National Cancer Institute, 2009). As disturbing as these statistics may 
be, they fail to illustrate the extent of human suffering (Roberts, 1998). They fail to 
describe the several major surgeries, multiple courses of chemotherapy treatment 
(with their associated toxic effects), bouts of bowel dysfunction and psychological 
trauma of battling cancer that these women will undergo before they die of their 
disease (Roberts, 1998). It is an extremely aggressive and deadly disease, difficult to 
detect in its early development stages, allowing it to “progress silently until it has 
metastasized to other organ systems”, (Anderson, 2009 & Helm et al., 2009).  
 
The focus of this study therefore concentrated on the genetic susceptibility of ovarian 
cancer patients through the observation of point mutations that occur within the 
transcription regulatory regions of genes that have been implicated in the disease. 
These tiny variations in the human genome known as single nucleotide 
polymorphisms (SNPs) are investigated here as a plentiful source of potential 
diagnostic markers to improve cancer diagnosis and treatment planning (Chakravarti, 
2001 & Thomas et al., 2004). Although typically SNPs have been used as markers to 
search for what may be considered the real determinant of a disease, the use of 
functional SNPs may be an important factor to be considered in the future of 
association studies and predictive medicine.  
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2.1 Predictive Medicine 
 
Deciphering the regulatory control mechanisms that govern gene expression will 
enable us to understand the processes underlying gene regulation and can be of crucial 
importance to the unraveling of biological processes within cells of the thousands of 
existing and anticipated patients affected by ovarian cancer (Wasserman et al., 2004 
& Alkema et al., 2004). Understanding the interplay between transcription factors and 
regulatory motifs in the upstream regions of genes will transform biological research 
and provide a means to interpret and model the responses of cells to diverse stimuli 
(Wasserman et al., 2004).  
 
2.2 Research Aims 
 
The aims for this research were as follows:  
 
(1) To assess the transcriptional regulation of ovarian cancer genes based on the 
inferred losses of putative transcription factor binding sites (TFBSs) caused by the 
occurrences of single nucleotide polymorphisms (SNPs). 
 
(2) To contribute toward the identification of potentially bio-medically important 
genes or SNPs for pre-diagnosis and therapy of ovarian cancer by evaluating the 
possible regulatory effects of SNPs among several population groups defined by the 
International HapMap consortium. 
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2.3 Research Objectives 
 
The objectives undertaken to achieve the above aims were as follows:  
 
(1) Identification and mining of candidate gene dataset (i.e. genes implicated in 
ovarian cancer). 
 
(2) Prediction of SNP occurrences within all candidate genes through the application 
of several online resources and custom programs.  
 
(3) Prediction of TFBSs on promoter regions of all genes via a positional weight 
matrix (PWM) approach to TFBS motif identification.  
 
(4) Determination of SNPs that overlap with TFBSs within candidate genes.  
 
(5) Identification of SNPs (i.e. SNPs that overlap with TFBSs) allele patterns among 
population groups defined by the International HapMap consortium.  
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CHAPTER 3 
 
 
Single Base Differences 
 
 
MORE than a decade ago, the debate of whose genome was to be sequenced began 
with the start of the Human Genome Project, as the study of inherited genetic 
variation between individuals was envisaged (Chakravarti, 2001). Ultimately 
geneticists resolved to “not only a single history-making human genome sequence, 
composed of little bits from many humans, but also more than 1.4 million sites of 
variation mapped along that reference sequence”, (Chakravarti, 2001 & 
Sachidanandam et al., 2001). These variations (or polymorphisms) are the most 
common types of variation between humans and may account for as much as 90% of 
human genetic variation (Chakravarti, 2001 & Tian et al., 2007). In 2001 the 
International SNP Map Working Group reported 93% of genes containing a SNP, 
when for the first time nearly every human gene and genomic region was marked by a 
sequence variation (Chakravarti, 2001). Today, more than 11 million SNPs have been 
described in databases such as dbSNP, and among them thousands that potentially 
impact on disease directly (Reumers et al., 2007).  
 
This chapter focuses on the identification of SNPs that potentially alter transcriptional 
activity and/or transcription factor binding among a collection of genes that have been 
differentially expressed in ovarian cancer. Through the application of several online 
resources and custom programs, the focal point of this chapter was on the elucidation 
of SNPs with potential phenotypic effects at a transcriptional level.  
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3.1 Introduction 
 
Genetic variation is a factor that has been associated, by several studies; with the 
susceptibility of diseases through the modification of amino acid sequences in DNA 
encoded proteins (GuhaThakurta et al., 2006). The phenotypes expressed by these 
variations include genetic susceptibility to diseases and resistance to therapeutic 
agents (Cardon et al., 2001). Single nucleotide polymorphisms (SNPs) provide a 
means for the testing of associations between genetic variations and disease, and have 
been hypothesized to having causal roles in the susceptibility to genetic disorders as a 
result of interferences within the regulatory regions of genes (Flintoft, 2004). 
 
With the onset of new expression techniques including data derived from microarray 
experiments, many in silico methods have been proposed and implemented for the 
identification of underlying biological information (Pavesi et al., 2004). Online 
resources containing biological knowledge have become vital to the work of many 
scientists around the world, with individual groups having given rise to a diversity of 
biological databases, tools and applications in the field.  
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3.1.1 Dragon Database for Exploration of Ovarian Cancer Genes  
(DDOC) 
 
The DDOC is a database dedicated to genes that have been implicated in ovarian 
cancer, developed to support exploration of functional characterization and analysis of 
biological processes related to the disease (Kaur et al., 2008). 
 
 
Figure 3.1 The "DDOC main page (South African National Bioinformatics Institute & 
OrionCell, 2009). Integrating several other tools, DDOC provides users with detailed 
information relating to homologs, regulatory mechanisms, pathways and text-mining 
results associated to the genes contained in this database (Kaur et al., 2008). 
 
DDOC contains a total of 379 human genes that have been verified experimentally 
and through literature mining, resulting in the exclusion of 521 of the initially derived 
900 genes that were unable to meet these criteria (Kaur et al., 2008).  
 
 
 
 
 
                                                
" http://apps.sanbi.ac.za/ddoc/ 
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Initial data mining of genes were collated from the following repositories:  
 
Repository URL 
 
Cancer Gene Census  
 
http://www.sanger.ac.uk/genetics/CGP/Census/ 
 
GeneCards  
 
http://www.genecards.org/index.shtml 
 
SymAtlas  
 
http://symatlas.gnf.org/SymAtlas/ 
 
OMIM  
 
http://www.ncbi.nlm.nih.gov/ 
 
Ovarian Kaleidoscope Database  
 
http://ovary.stanford.edu/ 
 
Entrez Gene  
 
http://www.ncbi.nlm.nih.gov/sites/entrez?db=gene 
 
GenAtlas  
 
http://www.genatlas.org/ 
 
 
HUGO gene symbols, full gene names and Entrez IDs are available for all genes 
within the DDOC database, with HGNC IDs provided for 374 genes and Ensembl IDs 
for 370 of the total genes (Kaur et al., 2008). The database additionally provides the 
user with "Gene Ontology (GO) annotations for 367 genes with 353 genes indexed in 
#eVOC (Kaur et al., 2008).  
 
Among other features, DDOC offers information that is not freely available to all 
researchers via their delivery of TFBS predictions mapped to promoter regions 
contained in the 1000bp upstream and 200bp downstream of the transcription start 
sites (TSSs) on all genes (Kaur et al., 2008). TFBSs were mapped to both the forward 
and reverse strands of these promoter regions using the MATCH
TM
 program from the 
Transfac
®
 Professional (Version 11.4) database (Kaur et al., 2008).  
 
                                                
" Gene Ontology (http://www.ebi.ac.uk/GO/) 
# eVOC (http://www.sanbi.ac.za/evoc/) 
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3.1.2 SNP@Promoter 
 
The SNP@Promoter tool is an integrated computational system for the identification 
of SNPs in non-coding regulated regions of genes (SNP@Promoter, 2007).  
 
 
Figure 3.2 The "SNP@Promoter main page. The main page may be queried via any of 
three term entries i.e. by entering a SNP identifier, gene name/symbol/RefSeq ID or by 
querying a disease term (Korean Bioinformation Center, 2007 & Kim et al., 2008). 
 
The underlying computational system of SNP@Promoter, defining the transcription 
regulatory region of a gene as "the sequence of 5kb upstream to 500bp downstream 
bases of a transcription start site", was developed specifically to determine the 
following key aspects of analysis (Korean Bioinformation Center, 2007 & Kim et al., 
2008):  
 
(1) Prediction of TFBSs in putative promoter regions 
(2) Identification of SNPs in putative promoter regions  
(3) Select SNPs within predicted TFBSs 
(4) Examine evolutionary conservation of predicted TFBSs 
(5) Integration of a variety of gene annotation information 
 
 
                                                
" http://variome.kobic.re.kr/SNPatPromoter/ 
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SNPs present on putative promoter regions were derived from dbSNP (build 126) 
while TFBSs were predicted using the MATCH
TM
 (Matrix Search for Transcription 
Factor Binding Site) program from Version 8.4 of the Transfac
®
 database (Kim et al., 
2008). As a result SNP@Promoter includes 1497317 TFBSs, from 28644 human 
genes mapped to 488452 SNPs, 47832 of which are located within the putative 
TFBSs (Kim et al., 2008). 
 
All annotation information that is mapped to the genes contained in this tool was 
obtained from the NCBI Gene database and can be viewed graphically for all queried 
genes and SNPs (Kim et al., 2008). 
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3.1.3 Functional Single Nucleotide Polymorphism (F-SNP) 
 
The F-SNP (Release 1.0) database integrates information obtained from 16 
independent bioinformatics tools and databases (Table 3.1) relating to the functional 
effects of SNPs, based on their effects at a splicing, transcriptional, translational or 
post-translational level (Lee et al., 2007).  
 
 
Figure 3.3 The "F-SNP main page (Queen’s University, 2007). Users may search the 
database by entering a SNP identifier, gene symbol, disease name/type or by selecting a 
chromosomal region.  
 
F-SNP combines a total of 38550 human genes along with their related information 
(i.e. gene symbol, alias names, chromosomal location, etc.), obtained from the NCBI 
Entrez Gene database as well as SNP annotation data sourced from the dbSNP (build 
126) and Ensembl (release 42) databases (Lee et al., 2007). Consequently, a total of 
4043147 SNPs located in the 5kb upstream and 5kb downstream regions were 
mapped to 23630 of these human genes (Lee et al., 2007).  
                                                
" http://compbio.cs.queensu.ca/F-SNP/ 
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Table 3.1 F-SNP data incorporation from several sources (Lee et al., 2007 & Karchin, 2008). To assess the functional effects of SNPs for each 
possible category of SNP type, F-SNP combines the functionalities of the following collection of tools: 
 
Tool Usage URL 
PolyPhen http://genetics.bwh.harvard.edu/pph/data/index.html 
SIFT http://blocks.fhcrc.org/sift/SIFT.html 
SNPeffect http://snpeffect.vib.be/index.php 
SNPs3D http://www.snps3d.org/modules.php?name=SNPtargets 
LS-SNP 
 
 
Identification of non-synonymous deleterious SNPs 
http://alto.compbio.ucsf.edu/LS-SNP/Queries.html 
ESEfinder http://rulai.cshl.edu/cgi-bin/tools/ESE3/esefinder.cgi 
RescueESE http://genes.mit.edu/burgelab/rescue-ese/ 
ESRSearch http://ast.bioinfo.tau.ac.il/ 
PESX 
 
Identification of SNPs in exonic splice regions 
http://cubweb.biology.columbia.edu/pesx/ 
Ensembl Identification of nonsense SNPs and SNPs in intronic splice sites http://www.ensembl.org/index.html 
TFSearch http://www.cbrc.jp/research/db/TFSEARCH.html 
Consite 
Identification of transcriptional regulatory SNPs in promoter regions 
http://asp.ii.uib.no:8090/cgi-bin/CONSITE/consite/ 
Ensembl http://www.ensembl.org/index.html 
GoldenPath 
Identification of SNPs in other transcriptional regulatory regions 
(e.g. microRNA, cpgIslands) http://genome.ucsc.edu/ 
KinasePhos http://kinasephos.mbc.nctu.edu.tw/ 
OGPET http://ogpet.utep.edu/ 
Sulfinator 
 
Examination of post-translational modification sites 
http://www.expasy.ch/tools/sulfinator/ 
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3.1.4 PupaSuite 
 
The PupaSuite (Version 2.0), developed by the Centro Nacional de Investigaciones 
Oncológicas (CNIO) is an interactive web-based SNP analysis tool that uses a 
collection of data on SNPs from several sources and combines the functionality of 
both PupaSNP and PupasView into a more integrated interface (Conde et al., 2006). 
Moreover, it implements new facilities such as the analysis of user data to derive 
haplotypes with functional information, as well as predictions by the SNPeffect 
database (Conde et al., 2006).  
 
 
 
Figure 3.4 The !PupaSuite main page (Centro de Investigacion Principe Felipe, 2008). 
Users may input their queries as lists of SNPs/genes or via chromosomal regions, which 
correspond to two common types of analyses, (1) genes that may be related to a disease 
because they are functionally related or (2) genes present in a chromosomal region 
linked to a disease (Conde et al., 2006). 
 
The PupaSuite tool selects SNPs for genotyping experiments that are often multigenic 
and reflective of disruptions in proteins that participate in protein complexes or 
pathways (Conde et al., 2006). The program also includes predictions for SNPs 
present in TFBSs, splice sites, silencers and miRNAs including their targets (Reumers 
et al., 2007).  
                                                
! http://pupasuite.bioinfo.cipf.es or http://www.pupasnp.org 
 
 
 
 
 34 
Table 3.2 Optimal SNP candidates as defined by the PupaSuite tool. In order for a SNP 
to be considered as an optimal candidate for genotyping purposes, the following three 
main features are taken into account (Conde et al., 2006): 
 
Criterion Description 
 
Minor allele frequency (MAF) 
 
Sourced from the Ensembl database (maps dbSNP 
data onto corresponding chromosomal coordinates) 
 
Linkage disequilibrium (LD) 
 
Calculated as r
2
 and D
0
 with the Haploview program 
 
Putative functional effect 
 
Estimated in both exons and introns 
 
 
TFBS identification is done using position weight matrices (PWMs) stored in the 
!JASPAR and "Transfac
®
 databases. JASPAR is an open-access database of 
annotated, high quality, matrix-based TFBS profiles for multi-cellular eukaryotes 
(Reumers et al., 2007 & Sandelin et al., 2004). Transfac
®
 is another important 
database that uses PWMs to identify TFBSs (Fu et al., 2005). Although the detailed 
algorithms to construct the PWMs in Transfac
®
 have not been published, it has been 
applied to several notable studies (Fu et al., 2005; Bozek et al., 2007; Bozek et al., 
2008; Frericks et al., 2008; Cai et al., 2009; Ridder et al., 2009 & Yang et al., 2009).  
 
PupaSuite uses matrices corresponding to vertebrates to search for TFBSs in the 5kb 
upstream region of all human genes (Reumers et al., 2007). The program additionally 
incorporates the use of the MatScan program (http://genome.imim.es) to search for 
binding sites in genomic sequences, however since it does not allow a cutoff to 
minimize false positives, the PupaSuite also uses the Meta program 
(http://genome.imim.es) to filter results by searching for coincidences of TFBSs in 
orthologous genes in the mouse genome (Reumers et al., 2007). 
 
 
 
 
 
                                                
! http://jaspar.cgb.ki.se/ 
" http://www.biobase-international.com/pages/index.php?id=transfac 
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3.1.5 dbSNP 
 
The dbSNP database, created by the National Centre for Biotechnology Information 
(NCBI), is a public-domain archive of SNPs originally established to address the 
large-scale sampling designs required by association studies and to assist in gene 
mapping and evolutionary biology research (Sherry et al., 2000 & Edvardsen et al., 
2006).  
  
 
Figure 3.5 The !dbSNP main page (National Center for Biotechnology Information, 
2008). “Users may query dbSNP directly or start a search in any part of the NCBI 
discovery space to construct a set of dbSNP records that satisfy their search conditions”, 
(Sherry et al., 2000).  
 
In 2006, dbSNP contained over 10 million SNPs, collated from more than 97 
registered groups with all records being cross-annotated within other NCBI-internal 
information resources (e.g. Pubmed, GenBank, LocusLink, etc.) (Sherry et al., 2000 
& Edvardsen et al., 2006).  
 
 
 
                                                
! http://www.ncbi.nlm.nih.gov/SNP 
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Today dbSNP contains more than 56 million SNPs mapped to 45 organisms (National 
Center for Biotechnology Information, 2006) designed to facilitate searches based on 
the following five key types of information (Sherry et al., 2000): 
 
(1) Sequence location 
(2) Function 
(3) Cross-species homology 
(4) SNP quality or validation status 
(5) Degree of population variation 
 
It is suggested that SNPs in the dbSNP database that have been reported by at least 
two independent groups are most likely to be considered true variants and success 
rates of genotyping projects for a selected number of SNPs are improved if SNPs 
have been validated in dbSNP (Carlson et al., 2003; Reich 2003 & Edvardsen et al., 
2006). 
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3.1.6 PROMEX: Dragon promoter extraction tool 
 
PROMEX is a promoter retrieval tool designed for the identification of transcription 
start sites (TSSs) and extraction of user-specified promoter regions upstream and 
downstream of the identified TSSs. 
 
 
 
Figure 3.6 The !PROMEX: Dragon promoter extraction tool main page (Schaefer, 2009). 
Users may query multiple sequence files in a single query by clicking on the “Browse” 
button and selecting the sequence file or pasting it into the text query box. The inclusion 
or exclusion of “CAGE” RNA libraries is a customizable feature and genes may be 
queried in the form of Entrez gene IDs, Gene symbols or Unigene cluster IDs.  
 
 
 
 
 
 
                                                
! http://tr.sanbi.ac.za/~ulf/promex/ 
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3.1.7 Matrix Search for Transcription Factor Binding Site 
(MATCHTM) 
 
MATCH
TM
 is a matrix-based search tool, designed to identify potential binding sites 
for transcription factors in DNA sequences (Kel et al., 2003; Matys et al., 2003 & 
Wasserman et al., 2004). 
 
 
Figure 3.7 The !MATCH
TM
 query page. MATCH
TM
 accepts DNA sequences as input 
then searches for potential TFBSs using a library of PWMs. The program then outputs a 
list of these predictions in text or graphical format, illustrating their locations within the 
submitted sequence (Kel et al., 2003). 
 
The search algorithm uses the following two score measures to assess the quality of a 
match between the query sequence and the matrix (Kel et al., 2003):  
 
(1) Matrix Similarity Score (MSS) 
(2) Core Similarity Score (CSS) 
 
Ranging from 0.00 to 1.00, TFBS predictions with a score of 1.00 are classified as 
exact matches (Kel et al., 2003).  
 
 
                                                
! http://www.gene-regulation.com/pub/programs.html#match 
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Both MSS and CSS scores are calculated using the same formula (Kel et al., 2003). 
While MSS is calculated using all matrix positions, CSS calculations are based only 
on the core positions within a matrix (Kel et al., 2003). Two corresponding cut-off 
scores (customizable) are defined for every matrix and only matches for which both 
scores are higher than these cut-offs are reported (Kel et al., 2003).  
 
To improve on the efficiency of the algorithm, a hash table is constructed for every 
five nucleotides (pentanucleotide) in the query sequence (Kel et al., 2003). The 
program then calculates and stores all CSS values for every five nucleotides into this 
hash table, before checking if the CSS value is higher than the initial cut-off value 
(Kel et al., 2003). If the CSS value is higher than the cut-off score, this 
pentanucleotide is then searched for in the whole query sequence and is prolonged at 
both ends to ensure that it fits the matrix length (Kel et al., 2003). The matrix 
similarity score is then calculated and only values higher than the cut-off value are 
reported (Kel et al., 2003).  
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3.1.8 Python 
 
Python is a general-purpose, freely available, object-oriented programming language 
that can be used for many kinds of software development, (Python, 2008). First 
released by Guido van Rossum in 1991, Python comes with extensive standard 
libraries and is a minimalist language both syntactically and semantically. It may be 
integrated into other languages and tools and is often used as a scripting language 
(Python, 2008). 
 
Python was used extensively in the parsing and handling of data generated and 
analyzed in this study, in addition to data/results obtained from the various tools 
applied in Sections 3.2.2.1, 3.2.2.3 - 3.2.2.5, 3.2.3 - 3.2.5 and 4.2.1. 
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3.2 Methodology 
 
The initial aspect of this project aimed at the prediction and validation of a panel of 
SNPs suitable for future disease association studies among women possessing one or 
more of the traits associated with an increased risk for ovarian cancer (Table 1.2).  
 
3.2.1 Selecting Candidate Genes 
 
The initial set of candidate genes were extracted from the Dragon Database for 
Exploration of Ovarian Cancer Genes (DDOC) (Section 3. 1.1). This data set included 
all entries stored within the database during February of 2008. All genes included in 
this data set were selected based on their gene expression via several experimentally 
proven techniques, excluding those tested by microarray technology. Since 
microarray technology only provides initial evidence of gene expression in certain 
cell types and is accompanied by associated limitations (i.e. high rate of false 
positives), determining any meaningful level of differential expression, statistical 
analysis or data interpretation were debatable and therefore excluded (Pritchard et al., 
2001 & Smyth et al., 2003). Genes that were experimentally proven by wet-laboratory 
techniques (Table 3.6) such as immunohistochemistry, western blotting, FISH 
(Fluorescent In Situ Hybridization), RT-PCR (Reverse Transcriptase-Polymerization 
Chain Reaction), etc. formed the final candidate gene data set.  
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Figure 3.8 Overview of methods applied to the candidate gene data set. Through the application of several tools and custom programs, the 
identification of SNPs coinciding with TFBSs was ultimately accomplished. 
 
 
 
 
 43 
An overview of the methods applied in this chapter can be categorized into 3 key parts as 
follows:  
 
PART 1 
The initial set of candidate genes, obtained from the Dragon Database for the Exploration 
of Ovarian Cancer Genes (DDOC) (File 1) was queried through three independent SNP 
annotation tools 1, 2 & 3 (i.e. F-SNP, SNP@Promoter & PupaSuite respectively) resulting 
in the generation of three comma delimited files (Files 2, 3 & 4) containing SNP 
predictions by each tool respectively. Custom programs html_read.py (Appendix I-B) and 
pupasuite_read.py (Appendix I-C) were applied to the SNP results obtained from the 
SNP@Promoter and PupaSuite tools to enable/ensure the compilation of comparable data. 
Custom program all_snps.py (Appendix I-D) was then applied to the SNP results contained 
in Files 2, 3, & 4 (i.e. F-SNP, SNP@Promoter & PupaSuite SNP predictions) resulting in 
the generation of another comma delimited file (File 5) containing a combination of all 
SNP results per gene by each of the SNP annotation tools. All SNP results, then contained 
in File 5, were thereafter verified by querying all RefSNP IDs in a single batch query 
through the dbSNP database (Section 3.1.5). The resulting flat file was downloaded and 
read into a fourth custom program (Appendix I-E) before being written to a sixth comma 
delimited file (File 6) as the final SNP reference table to be compared with the 
corresponding TFBS reference table (File 9) acquired in Part 2 below. 
 
PART 2 
Following the generation of a SNP reference table (File 6), a corresponding TFBS 
reference table with which to compare the SNP results was then determined. To do this, the 
promoter regions of all candidate genes were extracted by querying the Entrez IDs of all 
genes through the Promex promoter extraction tool (Section 3.1.6). All promoter regions 
were then obtained in a single flat file illustrated in Figure 3.8 as File 7. This file was then 
read into custom program label_promoters.py (Appendix I-F) to refine and display selected 
information for each title of all promoter sequences contained in the flat file (File 7). The 
resulting re-labeled flat file was then queried through the MATCH
TM
 TFBS prediction tool 
(Section 3.1.7) before obtaining TFBS predictions for each promoter region of all candidate 
genes in Microsoft Excel (.xls) format.  
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This result file was then converted into comma delimited file format (File 8) for 
consistency and comparability (i.e. with the SNP reference table created above), before 
being read into the match_read.py custom program (Appendix I-G) and output to a final 
TFBS reference table (File 9). 
 
PART 3 
In the final part of this chapter's methodology, the SNP reference table (File 6) was 
compared to the TFBS reference table (File 9) through the application of another custom 
program (Appendix I-H). All SNPs that were found to coincide with TFBSs were then 
exported to a tenth comma delimited file (File 10).  
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3.2.2 Identification & Verification of SNPs 
 
All candidate genes were screened for SNPs in silico through the implementation of 
three independent SNP annotation tools, as illustrated in Figure 3.8. These publicly 
available tools were utilized to avoid any bias as well as to ensure that any 
unforeseeable caveats within any one tool was compensated for by the application of 
a second and/or third tool. 
 
3.2.2.1 SNP@Promoter  
 
SNP predictions by SNP@Promoter (Section 3.1.2) were compiled by querying each 
candidate gene (Appendix I-A) one at a time through the tool via the “By Gene” text 
entry box, before clicking on the “Search” button. Entries matching the search query 
were then selected and all resulting webpages saved in Hyper Text Markup Language 
(.html) format to a local working directory. A custom program (Appendix I-B) 
designed to identify and extract all SNPs predicted per gene was then applied to the 
accumulated result files. Consequently, all SNP@Promoter results were compiled and 
exported to a comma delimited (.csv) file, reflecting the SNPs predicted in the 
following order: 
 
HUGO gene symbol | RefSNP identifier | Chromosomal location | Strand orientation | 
Nucleotide base position 
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3.2.2.2 F-SNP 
 
SNP predictions by F-SNP (Section 3.1.3) were manually collated by querying each 
candidate gene (Appendix I-A) one at a time through the tool. This was done first by 
selecting the “Query by Gene” option then entering the gene symbol into the text 
entry box entitled “Enter Gene Name” and clicking on the “Submit” button.  
 
Only SNPs present in any of the following F-SNP-defined genomic regions were 
selected and manually entered into a Microsoft Excel (.xls) spreadsheet:  
 
(1) “REGULATORY REGION, UPSTREAM” 
(2) “REGULATORY_REGION, 3PRIME_UTR” 
(3) “REGULATORY_REGION, DOWNSTREAM” 
(4) “REGULATORY_REG” 
(5) “REGULATORY_REGION, INTRONIC” 
(6) “REGULATORY_REGION, 3P” 
(7) “REGULATORY_REGION, 5” 
 
Results were compiled in the following order: 
 
HUGO gene symbol | RefSNP identifier | Chromosomal location | Strand orientation | 
Nucleotide base position 
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3.2.2.3 PupaSuite 
 
All candidate genes (Appendix I-A) were queried through the “SNP Prioritization” 
page of the PupaSuite tool (Section 3.1.4) under the following parameter 
specifications: 
 
Table 3.3 PupaSuite parameter specifications.  
 
Option Sub-Option Status 
 
Organism 
-  
Homo sapiens 
 
Select your data 
-  
Gene list 
 
TRANSFAC/Match predictions 
 
Checked 
 
Regulatory properties 
 
JASPAR/MatScan predictions 
 
Checked 
 
 
SNP predictions resulting from this query were received individually for Transfac and 
Jaspar results, in the form of two Microsoft Excel (.xls) files that were subsequently 
downloaded and converted into comma delimited file format to be used as an input 
file for the custom program shown in Appendix I-C. This script was designed to 
collate all SNPs predicted per gene by both Transfac and Jaspar, storing the sorted 
results into a new comma delimited file (.csv). 
 
3.2.2.4 Accumulative SNP Predictions 
 
Following the SNP predictions by the SNP@Promoter, F-SNP and PupaSuite tools, a 
custom program (Appendix I-D) designed to read through all result files from each of 
these tools was applied, creating a combined list of these SNP predictions. However, 
due to the absence of nucleotide base positions associated with each of the SNPs 
predicted by the PupaSuite tool, an initial file was created inclusive of all SNP 
predictions by the SNP@Promoter and F-SNP tools. This file was then scanned for 
RefSNP IDs contained within the PupaSuite result file, thereby confirming a 
percentage of the SNP predictions obtained by the PupaSuite tool.  
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3.2.2.5 SNP Verification 
 
Verification of the accumulated SNP predictions began on the dbSNP main page, 
where under the "Batch" subheading, "References SNP ID (rs)" was selected. 
Subsequently, on the query page, a valid email address was provided (for receipt of 
results) in the "Email" text field; "Homo sapiens" was selected from the drop down 
menu below the "Organism" subheading and RefSNP (i.e. rs) IDs of all accumulative 
SNPs were then pasted into the query box below the "Enter RS Numbers" 
subheading. Finally, the "Flat file" option was selected as the preferred output format 
in the "Select Result Format" drop-down menu, before clicking on the "Submit" 
button.  
 
Results were received in flat file format and downloaded to the working directory 
before being read into the verify_snps.py custom program (Appendix I-E) designed to 
search for SNPs reflected in both the accumulative SNP list derived in Section 3.2.2.4 
and the dbSNP result file.  
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3.2.3 Promoter Sequence Retrieval 
 
The first step in the identification of functional regulatory regions that control 
transcription rates was to locate and extract each of the genes’ promoter regions. The 
promoter regions tend to be proximal to the initiation site(s) of transcription within 
any one gene (Qiu, 2003 & Wasserman et al., 2004). Although there are no definite 
guidelines for the promoter-collection process, regulatory sequences are sought near 
transcription start sites (TSSs), as they are more likely to contain functionally 
important regulatory controls (Wasserman et al., 2004).  
 
In this study the promoter region was defined as the 2000bp upstream and 500bp 
downstream region, proximal to the gene’s TSSs (i.e. -2000 - 500). Entrez IDs of all 
candidate genes were retrieved from the DDOC database (Section 3.1.1) and compiled 
into a flat file (one entry per line) before being uploaded into the PROMEX: Dragon 
promoter extraction tool (Section 3.2.6) under the following parameter specifications: 
 
Table 3.4 PROMEX query specifications. Genes were queried via the CAGE FANTOM 
analysis page subject to the following parameter specifications: 
 
Parameter Setting 
 
Database 
 
FANTOM3 - H.Sapiens 
 
Type of input parameter 
 
Entrez gene ID 
 
Distance 
 
50000 
 
Min. # of tags 
 
5 
 
Min. # of tags in representative tag 
 
3 
 
# of nucleotides upstream  
 
2000 
 
# of nucleotides downstream  
 
500 
 
Verify data 
 
Checked 
 
 
Results were received in the form of a flat file containing all promoter regions per 
gene and subsequently refined through the application of the label_promoters.py 
custom program (Appendix I-F).  
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This program (Appendix I-F) combined all HUGO gene symbols and corresponding 
Entrez IDs (sourced from the DDOC database) with the results from PROMEX, 
creating a new flat file with summarized titles for all promoter sequences predicted by 
PROMEX. All titles were concatenated into a string type label and arranged 
chronologically in the following order: 
 
1. HUGO gene symbol 
2. Strand orientation 
3. Chromosomal location 
4. Promoter sequence start position (bp) 
5. Promoter sequence end position (bp)  
 
The program (Appendix I-F) was run via the command line interface with the newly 
labeled promoter sequences piped to an output text file using the following command 
from the working directory: 
 
“python label_promoters.py > promex_relabeled_promoters.txt” 
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3.2.4 Identification of TFBSs 
 
In the search for SNPs with potential phenotypic effect, all promoter regions 
identified above (Section 3.2.3) consisting of 2000bp upstream and 500bp 
downstream region of all TSSs from each candidate gene was scanned for the 
presence of TFBSs.  
 
To determine TFBSs present within these promoter regions, MATCH
TM
 (Version 
11.4) (Section 3.1.7) from the Transfac
®
 Professional (Version 11.4) database was 
used under the following parameter specifications: 
 
Table 3.5 MATCH
TM
 parameter specifications.  
 
Parameter Setting 
 
Upload a file 
 
Promex_Relabeled_Promoters.txt 
 
Profiles 
 
vertebrate_non_redundant_minFP 
 
Use only high quality matrices 
 
Checked 
 
minimize false positives  
 
Checked 
 
 
Results were received in the form of a flat file before being read into the 
match_read.py custom program (Appendix I-G) designed to filter through these 
results, isolating TFBS predictions per gene in the following order before storing 
results into a new comma delimited (.csv) file: 
 
HUGO gene symbol | Strand orientation | Chromosomal location | TFBS (Nucleotide 
base position [Start-Stop]) | Transcription Factor | Matrix Identifier 
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3.2.5 Elucidating SNP-TFBS Overlap 
 
For the elucidation of SNPs that occurred within TFBSs, the overlaps.py custom 
program (Appendix I-H) was applied to the data obtained from the MATCH
TM
 results 
in Section 3.2.4 and final list of verified SNPs resulting from Section 3.2.2.5. This 
program (Appendix I-H) was designed to identify SNP-TFBS overlap by cross 
matching two comma delimited (.csv) files (Figure 3.8, Files 6 and 9) for the 
elucidation of coinciding pairs.  
 
Figure 3.9 Determination of SNPs that coincide with TFBSs. Due to the binding of 
transcription factors (i.e. represented by the green molecule) across more than a single 
nucleotide base position (i.e. in this case positions d1, e1 & f1), SNPs that were predicted 
at any one of these positions were classified as SNPs coinciding within TFBSs.  
 
Coinciding SNPs and TFBSs were exported into a comma delimited output file 
(Figure 3.8, File 10) from the overlaps.py program (Appendix I-H) as illustrated by 
Figure 3.8.  
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3.3 Results 
 
3.3.1 Ovarian Cancer Candidate Gene Dataset 
 
A total of 379 candidate genes were extracted from the Dragon Database for the 
Exploration of Ovarian Cancer Genes (DDOC). These genes were observed among 22 
of the 23 human chromosomes as illustrated below.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10 Chromosomal distributions of candidate genes. Chromosomes 1, 11 and 19 
each comprise of more than 30 of the genes implicated in ovarian cancer with 
chromosome Y expectedly containing none of the candidate genes.  
 
All candidate genes contained within the Dragon Database for the Exploration of 
Ovarian Cancer Genes (DDOC) were experimentally tested via any one of 28 
techniques shown in Table 3.6.  
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Table 3.6 List of techniques employed in the experimental testing of the candidate gene 
data set. All techniques used to validate or experimentally prove the association between 
genes included in the DDOC and ovarian cancer, have been through laboratory-based 
analysis.  
 
Number Technique 
1 Immunoassay 
2 Cell lysis 
3 Cell proliferation assays 
4 Chemiluminescence Immunoassay 
5 Combined Bisulfite Restriction Analysis (COBRA) 
6 Denaturing High Performance Liquid Chromatography (DHPLC) 
7 Electrophoretic mobility shift assays 
8 Platinum/Paclitaxel-based Chemotherapy 
9 Facs analysis 
10 FISH (Fluorescent In Situ Hybridization) 
11 Flow Cytometry 
12 Immunoblotting 
13 Immunocytochemistry 
14 Immunofluorescence 
15 Immunohistochemistry 
16 In situ hybridization 
17 Mass spectrometry 
18 Methylation-specific PCR 
19 Microscopy 
20 Northern blotting 
21 Polymerase Chain Reaction 
22 ELISA 
23 RT-PCR 
24 Radioimmunoassay 
25 SDS-PAGE Gelatin Zymography 
26 SNP analysis 
27 Southern blotting 
28 Western blotting 
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Three techniques: immunohistochemistry, RT-PCR and western blotting were 
observed to have been used more extensively than the remaining 25 techniques listed 
in Table 3.6.  
 
Figure 3.11 Foremost techniques employed in the experimental proof of the candidate 
gene data set. Technique numbers 15, 23 and 28 were observed to be the most widely 
used in the experimental testing of candidate genes. These correspond (Table 3.6) to the 
analysis of 22 candidate genes studied via immunohistochemistry; 65 studied via RT-
PCR and 26 analyzed through western blotting.  
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3.3.2 Identification & Verification of SNPs 
 
A total of 10863 SNPs were predicted by the SNP@Promoter, F-SNP and PupaSuite 
tools, denominated as shown in Figure 3.12 below. From the total of 10863 SNPs 
predicted, 97% of these SNPs were obtained from SNP@Promoter, with 3% arising 
from F-SNP. PupaSuite results (i.e. SNP predictions by Transfac and Jaspar) 
amounted to a total of 90 SNPs, 42 of which were identified in the accumulated 
SNP@Promoter and F-SNP result file (Figure 3.8, File 6).  
 
 
Figure 3.12 Total numbers of SNPs predicted by each of the SNP annotation tools used 
for ovarian cancer candidate gene analysis. SNP predictions by SNP@Promoter account 
for the largest percentage of SNP results as this tool was designed to analyze the 
regions 5kb upstream to 500bp downstream of the transcription start sites of genes and 
all SNP predictions obtained by this tool were included in this study. In comparison, only 
SNPs specifically occurring within putative TFBSs (Table 3.3) or regulatory regions 
(Section 3.2.2.2) were included from the PupaSuite and F-SNP tools. 
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The SNP@Promoter tool was able to analyze a total of 360 of the 379 candidate 
genes, with four genes observed to contain a noticeably high number of SNPs (i.e. 
more than 100 SNPs) when compared to the numbers of SNPs predicted on the 
remaining 356 candidate genes.  
 
Figure 3.13 Frequency of SNP occurrences on candidate genes as predicted by the 
SNP@Promoter tool. HLA-type D genes HLA-DRB1 and HLA-DQA1 were observed to 
contain the highest numbers of SNPs when compared to the remaining 358 candidate 
genes that were analyzed, with 605 and 469 SNPs present on each respectively. HBB 
and BAGE, similarly, were found to contain 295 and 181 SNPs respectively. All other 
candidate genes contained an average of approximately 25 SNPs per gene. 
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The F-SNP tool was able to identify SNPs present within regulatory regions (Section 
3.2.2.2) on a total of 128 of the 379 candidate genes (Appendix I-A), with four genes 
observed to contain a noticeably high number of SNPs (i.e. more than 15 SNPs) when 
compared to the numbers of SNPs predicted on the remaining 124 candidate genes. 
 
 
Figure 3.14 Frequency of SNP occurrences on candidate genes as predicted by the F-
SNP tool. HLA-type D genes, HLA-DRB1 and HLA-DQA1 were observed to contain the 
highest numbers of SNPs once again when compared to the other 126 candidate genes 
that were analyzed. F-SNP identified 34 SNPs on HLA-DRB1 with 29 SNPs found on 
HLA-DQA1. TUSC3 and IL6 were found to contain 27 and 17 SNPs respectively, while 
all other candidate genes (i.e. excluding HLA-DRB1, HLA-DQA1, TUSC3 and IL6) 
contained an average of approximately 2 SNPs per gene identified within a regulatory 
region. 
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The PupaSuite tool was able to analyze 371 of the 379 candidate genes with one gene 
observed to contain a noticeably large number of SNPs predicted within putative 
TFBSs when compared to the numbers of SNPs predicted within TFBSs among the 
other 370 candidate genes that were analyzed. 
 
Figure 3.15 Frequency of SNP occurrences within putative transcription factor binding 
sites on candidate genes as predicted by the PupaSuite tool. A total of 20 SNPs were 
identified within putative TFBSs on the CSF2 gene, noticeably higher than the SNP 
predictions obtained for any other candidate gene. From the total of 371 candidate genes 
that were analyzed, only 34 genes (excluding CSF2) were found to contain an average of 
approximately 2 SNPs within a putative TFBS per gene.  
 
From the overall number of SNPs identified by the SNP@Promoter, F-SNP and 
PupaSuite tools, 10773 were verified via comparison with SNPs in the dbSNP (Build 
129) database (i.e. 133 unverified) and included in the final comparison with TFBS 
predictions described in Section 3.2.5. 
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3.3.3 Promoter Sequence Retrieval 
 
A total of 1155 promoter regions were obtained (Section 3.2.3) from the 379 
candidate genes (Appendix I-A). This correlates to approximately 3.0395 transcription 
start sites (TSSs) predicted per gene within the 2000bp upstream and 500bp 
downstream genomic regions.  
 
3.3.4 Identification of TFBSs 
 
TFBS results from the MATCHTM tool were based on the criteria specified in Table 
3.5, which ensured the reduced number of random sites found by the tool and 
inclusion of putative sites only with a good similarity to the weight matrix selected. 
 
 
 
Figure 3.16 MATCH
TM
 tabulated result output. All matches that were higher than the cut-
off scores and able to fulfill the parameter specifications described in Section 3.2.4 were 
reported in this result spreadsheet containing the matrix ID, position of the match, strand 
orientation (forward (+) or reverse (-)), core similarity score, matrix similarity score and 
corresponding nucleotide sequences and names of transcription factors associated with 
the TFBSs identified.  
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Figure 3.17 TFBS distribution between the 2000bp upstream to 500bp downstream 
promoter regions of all candidate genes. From the total of 6796 TFBSs predicted by the 
MATCH
TM
 tool, the highest concentration of TFBSs were found to be present within the 
upstream regions of approximately 200 to 1400bp of the TSS (indicated by the dense 
green frequency of TFBS predictions highlighted between the red margins (upper -200 to 
lower -1400)), with fewer TFBSs observed further away from the TSS (0bp).  
 
3.3.5 Elucidating SNP-TFBS Overlap 
 
Following the methodologies applied in Section 3.2.5 of this chapter, a list of 121 
SNPs overlapping with TFBSs were found on a total of 121 of the ovarian cancer 
candidate gene data set (Appendix I-I). From these overlapping regions, 57 unique 
transcription factors that bind to these putative TFBSs were implicated and are shown 
in Table 3.7 below. 
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Table 3.7 Transcription factors found to occur at binding sites that coincide with the 
occurrence of SNPs. Shown here is a non-redundant list of the 121 transcription factors 
that were implicated by the occurrence of SNPs within the binding sites of these TFs. 
 
Number 
 
Transcription 
factor 
Number 
 
Transcription 
factor 
Number 
 
Transcription factor 
 
1 AIRE 20 GATA-4 39 S8 
2 Pax-4 21 c-Ets-1 40 Ets 
3 HIF1 22 FAC1 41 LRF 
4 TBX5 23 ETF 42 SREBP 
5 Tal-1beta:E47 24 YY1 43 CP2/LBP-1c/LSF 
6 myogenin 25 SREBP-1 44 GR 
7 PLZF 26 ZF5 45 C/EBPdelta 
8 Hand1:E47 27 CACD 46 v-Myb 
9 Pax 28 POU3F2 47 AP-2alpha 
10 CDP 29 Pax-8 48 PPARalpha:RXRalpha 
11 Pax-5 30 Tax/CREB 49 CdxA 
12 AP-2 31 Cart-1 50 c-Ets-1(p54) 
13 Pax-3 32 Pax-2 51 POU6F1 
14 RFX 33 C/EBP 52 E2F 
15 GATA-X 34 ER 53 STAT 
16 MyoD 35 Spz1 54 HIC1 
17 Pax-6 36 HNF3alpha 55 VDR 
18 Sp1 37 1-Oct 56 MRF-2 
19 WT1 38 Egr-1 57 Muscle 
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3.4 Summary 
 
This chapter focused on the elucidation of single nucleotide polymorphisms that 
overlapped with transcription factor binding sites within genes that have been 
differentially expressed in ovarian cancer. In doing so, a total of 379 candidate genes 
that have been experimentally associated with ovarian cancer were obtained for 
analysis. These genes were queried through three independent publicly available SNP 
annotation tools before being verified through a public SNP repository. All verified 
SNPs were collated into a SNP reference table including the following fields 
respectively: (1) HUGO gene symbol of gene within which SNP was identified, (2) 
RefSNP ID of SNP, (3) Chromosomal location of SNP, (4) Strand orientation of gene 
on which the SNP was located (i.e. forward or reverse) and (5) Nucleotide base 
position of SNP occurrence.  
 
To determine if these SNPs coincided with putative TFBSs on any of the candidate 
genes, a TFBS reference table was also assembled with which to compare the SNP 
reference table to. This was done by extracting the promoter regions of all candidate 
genes and querying these regions through the MATCH
TM
 tool. All results obtained 
from this step were collated into a TFBS reference table including the following fields 
respectively: (1) HUGO gene symbol of gene within which TFBS was predicted, (2) 
Strand orientation of promoter sequence on which the TFBS was predicted (i.e. 
forward or reverse), (3) Chromosomal location of gene on which TFBS was 
predicted, (4) TFBS start and stop nucleotide base positions, (5) Transcription factor 
that binds at the predicted TFBS, (6) the Matrix identifier of the TFBS predicted (7) 
Matrix Similarity Score (MSS) of the prediction and (8) the Core Similarity Score 
(CSS) of the prediction.  
 
The use of a custom program (Appendix I-H) to compare the TFBS and SNP 
reference tables resulted in the elucidation of 121 SNPs that were found to coincide 
with TFBSs on 121 of the original 379 candidate genes (Appendix I-I). These SNPs 
are considered to have a putative phenotypic effect in the expression of the genes in 
which they were found by influencing the binding of transcription factors (Table 3.7) 
at these sites.  
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CHAPTER 4 
 
 
Population Association 
 
 
ASSOCIATING DNA variants with diseases has been used widely to identify regions of 
the genome and candidate genes that contribute to disease (Cardon et al., 2001). SNPs 
are, as a result of this, generally used for association studies to identify genes partly 
responsible for complex diseases (Xu et al., 2005). Theoretically, identifying common 
SNPs associated with a disease would involve the time-consuming and expensive task 
of genotyping millions of SNPs in individuals with and without a disease, before 
searching for sites that differ in frequency between the sampled groups (Manolio et 
al., 2008).  
 
SNPs have been proposed, by some, as the new frontier for population studies with 
several papers having presented evidence reporting the advantages and limitations of 
this type of diagnostic marker (Morin et al., 2008). To benchmark the in silico 
identified SNPs established in chapter 3 of this study, each of the 11 population 
groups defined by the International HapMap Project were analyzed for the presence 
of these SNPs. The aim of this chapter therefore was to examine several population 
groups for the observation of SNPs or SNP patterns that have been found to coincide 
with transcription factor binding sites (TFBSs) in chapter 3 of this study (Appendix I-
I). Through the combination of HapMap project data and the application of Perl 
(Section 4.1.2) and Python (Section 3.1.8) custom programs, these SNPs or SNP 
patterns are intended to constitute a suitable and more widely applicable basis for a 
SNP profile able to detect the presence of ovarian cancer before it is able to become 
invasive. 
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4.1 Introduction 
 
The use of population studies for insights into complex genes are giving researchers 
an advantage in identifying single gene defects despite their value in researching 
complex genes having been questioned (Peltonen et al., 2000; Tabor et al., 2002 & 
Luikart et al., 2003). Association studies may be the best approach to the study of 
genetic features of population isolates and potentially unlock the genetics of complex 
diseases (Peltonen et al., 2000 & Tabor et al., 2002). Complex diseases differ in 
severity of symptoms and age of onset, and can show variance in the numerous 
biochemical pathways that they may influence, however small insights into the 
population dynamics of candidate genes have a greater statistical efficiency and a key 
advantage in the understanding of tissues, genes and proteins involved in disease 
(Tabor et al., 2002 & Balding, 2006). With single gene defects, phenotypes can be 
diagnosed reliably and haplotype signatures used to map genes (Peltonen et al., 2000). 
Careful dissection of disease phenotypes is required to minimize genetic 
heterogeneity, and haplotype mapping essential as follow-up to linkage analysis 
(Peltonen et al., 2000). 
 
Linkage disequilibrium (LD) analysis is required to map disease genes by association 
(Peltonen et al., 2000 & Tabor et al., 2002), with analysis of disease genes and 
variable markers or haplotypes depending strongly on the understanding of linkage 
disequilibrium (Tishkoff et al., 2002). Haplotypes may have LD patterns that are 
distinct in various populations and may be subjected to SNP influence in varying 
levels of frequency (Tishkoff et al., 2002). By investigating candidate SNPs in 
combination with population genetics scientists have discovered a formidable 
foundation within which to identify disease-related genes in humans through the 
application of computational and statistical methods (Luikart et al., 2003). 
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Other statistical approaches in population studies have been suggested by Balding 
(2006), who found that use of the Hardy-Weinberg equilibrium test infers more 
accurately occurring SNPs or haplotypes from genotypes (Balding, 2006). Combined 
with association tests such as case-control phenotypes this has potentially provided 
future researchers with a greater insight into genetic associations (Tishkoff et al., 
2002 & Balding, 2006). These methods, when conducted in tandem with 
environmental epigenomics and disease susceptibility may provide the key to 
mapping the control of ovarian cancer. The epigenomics, which include genomic 
imprinting and monitors slight changes in gene expression, have already given rise to 
a greater understanding of developmental disorders associated with imprinted regions 
and genes (Jirtle et al., 2007). Imprinted gene deregulation or mutation increases 
cancer risk, as a single mutation or epigenetic event is required to completely 
inactivate imprinted tumor suppressor genes, as imprinting functionally inactivates 
one allele (Jirtle et al., 2007). 
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4.1.1 HapMap Genome Browser (GBrowse) 
 
Despite there being a number of public online resources developed to provide high-
volume genome-wide data sets such as the UCSC Genome Browser 
(http://genome.ucsc.edu) and EnsEMBL project (www.ensembl.org), the lack of 
flexibility for combining data from within and between each database does not allow 
for the calculation of key population variability statistics (Jorge et al., 2008 & Smith, 
2008a). The HapMap Genome Browser (GBrowse) was created with this distinct 
focus (Smith, 2008a). GBrowse aims to be a resource capable of retrieval, display and 
analysis of high-throughput and high quality genome-wide human genetic variation 
with an emphasis on disease association studies (Smith, 2008a).  
 
 
 
Figure 4.1 View of the !HapMap Genome Browser (GBrowse) main page after 
submission of a query term. Depending on the computer language settings, this page 
can appear in one of several languages, displaying a range of results pertaining to the 
query term under user-specified subheadings (Smith, 2008b). 
 
Users may query the GBrowse tool by entering any of the following search terms into 
the "Landmark or Region" search box: 
(1) Chromosome name (e.g. "Chr10") 
(2) Chromosomal start to stop position (e.g. "Chr10:25000..30000") 
                                                
! http://hapmap.org/cgi-perl/gbrowse/hapmap27_B36/ 
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(3) Reference SNP Identifier (e.g. "rs12345") 
(4) NCBI RefSeq Accession Number (e.g. "NM 12345") 
(5) HUGO Gene Symbol (e.g. "BRCA1") 
(6) Chromosomal band (e.g. "5q31") 
 
In this study the "HapMap Genome Browser (Phase 1, 2 & 3 - merged genotypes & 
frequencies)" project data was selected for the survey of SNPs occurring among a total 
of 11 population groups shown in Table 4.1. 
 
Table 4.1 List of population group samples that are included in the HapMap Phase 3 
project data set. The HapMap Phase 3 project data set includes the collection of 1301 
samples (i.e. including the original 270 samples from Phase 1 and 2 of the project) from 
11 population groups listed alphabetically here by their 3-letter labels (Broad Institute, 
2008).  
 
Label Population Sample Number of 
Samples 
ASW African ancestry in Southwest USA 
 
90 
CEU Utah residents with Northern and Western European ancestry  
 
180 
CHB Han Chinese in Beijing, China 
 
90 
CHD Chinese in Metropolitan Denver, Colorado 
 
100 
GIH Gujarati Indians in Houston, Texas 
 
100 
JPT Japanese in Tokyo, Japan 
 
91 
LWK Luhya in Webuye, Kenya 
 
100 
MEX Mexican ancestry in Los Angeles, California 
 
90 
MKK Maasai in Kinyawa, Kenya 
 
180 
TSI Toscans in Italy 
 
100 
YRI Yoruba in Ibadan, Nigeria 
 
180 
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This release of HapMap project data includes SNP genotype data that has been 
generated from 1115 (558 males, 557 females) of the 1301 total samples collected, 
using either of two platforms (i.e. Illumina Human1M and Affymetrix SNP 6.0) 
(Broad Institute, 2008). It also includes PCR-based resequencing data across ten 
100kb regions in 712 samples contributed by the Baylor College of Medicine Human 
Genome Sequencing Center (Broad Institute, 2008).  
 
Data from the two platforms were merged using PLINK ("--merge-mode 1") and 
include only genotype calls with a consensus between non-missing genotype calls (i.e. 
merged genotype was set to missing if the two platforms gave different "non-missing 
calls") (Broad Institute, 2008). Quality control at the individual sample level was 
performed separately and includes only individuals with genotype data that were 
present on both platforms (Broad Institute, 2008). Only SNPs that satisfied the 
following criteria were included in the HapMap phase 3 data release (Broad Institute, 
2008): 
 
 (1) Hardy-Weinberg p-value of more than 0.000001 (per population) 
(2) Missingness value less than 0.05 (per population) 
(3) Less than 3 Mendel errors (per population; only applied to YRI, CEU, ASW, 
MEX & MKK) 
(4) SNP must have a RefSNP Identifier and map to a unique genomic location 
 
4.1.2 Perl 
 
Originally developed by Larry Wall in 1987 as a general purpose Unix scripting 
language, Perl is a "high-level, interpreted, dynamic" language that provides powerful 
text processing facilities (Wall et al., 2000). Perl is used for graphics programming, 
system administration, network programming, CGI programming and applications 
that require access to databases (Wall et al., 2000). It is a flexible and adaptable 
language that was designed to be practical while borrowing features from other 
programming languages such as “C, shell scripting, AWK and sed”, (Wall et al., 2000).  
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4.2 Methodology 
 
4.2.1 SNPs vs. Population Groups  
 
The HapMap Genome Browser (GBrowse) was used to determine the prevalence of 
SNPs within the candidate gene dataset (Appendix I-A) among all population groups 
defined by the International HapMap Project. Each gene was queried one at a time 
through the GBrowse tool, via the application of the read_hapmap.pl custom program 
(Appendix II-A) created in Perl (Section 4.1.2). This program was run from the 
command line interface using the following commands, respectively: 
 
1 “perl read_hapmap.pl candidate_genes.txt fwd fwd_results” 
2 “perl read_hapmap.pl candidate_genes.txt rev rev_results” 
 
Command 1 was used to obtain all SNPs on the forward strands of all population 
groups for each candidate gene before storing these results into an output folder 
entitled “fwd_results”. Command 2 was used to obtain all SNPs on the reverse strands 
of all population groups for each candidate gene before storing these results into an 
output folder entitled “rev_results”. 
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Figure 4.2 Overview of methods applied to the identification of commonly occurring SNPs within HapMap-defined population groups. 
Through the application of custom programs, the identification of commonly occurring SNPs within all 11 population groups in the HapMap 
project’s Phase 3 data release was accomplished.  
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The overview of methods applied in this Chapter can be categorized into 2 key parts 
as follows:  
 
PART 1 
The HUGO gene symbols of all candidate genes (Appendix I-A) were queried one at a 
time through the HapMap Genome Browser (GBrowse) tool through the use of 
custom program read_hapmap.pl (Appendix II-A), resulting in the collection of 
genotyped SNP data for all 379 candidate genes per population group (i.e. included in 
HapMap Phase 3 data) on both the forward and reverse strands.  
 
PART 2  
All SNP genotype data obtained from the HapMap GBrowse tool were then filtered 
using the filter_hapmap.py custom program (Appendix II-B). 
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4.3 Results 
 
4.3.1 SNPs vs. Population Groups 
 
Following the application of the read_hapmap.pl program in Section 4.2.1, a total of 
8338 flat files containing SNP predictions for each candidate gene (i.e. on the forward 
and reverse strands) among all 11 population groups were obtained and stored into a 
single working directory.  
 
From the total of 5865604 SNPs predicted on the forward strands and 5878560 SNPs 
on the reverse strands of all population groups, 23852 common SNPs (i.e. present on 
all of the 11 population groups listed in Table 4.1) were identified on the forward 
strands with 24133 SNPs common SNPs identified on the reverse strands. 
 
4.3.2 HapMap SNPs Coinciding with TFBSs 
 
From the list of 121 SNPs identified in chapter 3 (Table 3.7) that were found to 
coincide with TFBSs, only 3 SNPs (Table 4.2) were identified among the 11 
population groups in the HapMap phase 3 project data.  
 
An overall average of the core similarity and matrix similarity scores for all three 
predictions by MATCH
TM
 revealed a 95.55% chance that the TFBSs for the C/EBP, 
CP2/LBP-1c/LSF and CDP transcription factors were present on genes E2F5, 
TNFRSF10A and CIITA respectively. SNPs rs4150842, rs20577 and rs12928665 
presented new alleles to these genes in varying degrees among each of the population 
groups sampled by the HapMap consortium (Table 4.1) as indicated in Table 4.3.  
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Table 4.2 List of SNPs coinciding with TFBSs that were identified among population 
groups included in the HapMap Phase 3 project data. SNPs predicted on genes E2F5, 
TNFRSF10A and CIITA that potentially influence the binding of transcription factors 
C/EBP, CP2/LBP-1c/LSF and CDP respectively have been predicted with reasonably 
high core similarity and matrix similarity scores.  
 
Gene RefSNP ID Nucleotide 
base position 
Transcription 
factor affected 
CSS MSS 
E2F5 rs4150842 86277150 C/EBP 0.997 0.997 
TNFRSF10A rs20577 23138422 CP2/LBP-1c/LSF 1 0.918 
CIITA rs12928665 10878975 CDP 1 0.839 
 
 
CSS and MSS values of 0.997 for the prediction of C/EBP at nucleotide position 
86277150 on the promoter region of the E2F5 gene suggests a 99,7% chance that this 
transcription factor occurs at this position on the forward strand of this gene. 
Similarly, there was a 95% chance that the CP2/LBP-1c/LSF transcription factors 
occurred at position 23138422 of the reverse strand of the TNFRSF10A gene and a 
91.95% chance that CDP occurred at position 10878975 on the forward strand of the 
CIITA gene.  
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Table 4.3 Allele frequencies of SNPs coinciding with TFBSs that were identified within HapMap population groups. SNP rs12928665 was observed 
within all 11 population groups, whereas SNPs rs4150842 and rs20577 were only identified in 5 and 9 population groups, respectively.  
 
rs# Allele ASW CEU CHB CHD GIH JPT LWK MEX MKK TSI YRI 
C 97% 100% N/A N/A N/A N/A 97% 99% N/A N/A 97% rs4150842 
T 3% 0% N/A N/A N/A N/A 3% 0% N/A N/A 3% 
G 74% 0% 0% 98% 99% 0% 74% N/A 89% N/A 68% rs20577 
A 26% 100% 100% 2% 1% 100% 26% N/A 11% N/A 32% 
A 78% 76% 44% 42% 64% 40% 84% 87% 81% 74% 88% rs12928665 
G 22% 24% 56% 58% 36% 60% 16% 13% 19% 26% 12% 
 
Subsequent to the observation of the ancestral nucleotide bases (within the TFBSs corresponding to transcription factors C/EBP, CP2/LBP-
1c/LSF and CDP) on genes E2F5, TNFRSF10A and CIITA, the frequencies of each allele for all SNPs were examined. SNP rs4150842 was 
observed to be present in percentages of 97% or higher in the ASW, CEU, LWK, MEX and YRI population groups, indicating a 3% or lower 
chance that the minor allele (T) for these groups would be present. This would indicate that in 97% or above of the cases that the rs4150842 SNP 
occurred, the C/EBP transcription binding to its corresponding The TFBS constituting the ancestral allele of this SNP, would in most cases be 
present in its ancestral allele form. For percentages of 3% or lower, that showed the presence of the minor allele, SNP rs4150842 would present 
a hindrance or influence the binding of the C/EBP molecule to its corresponding TFBS in the ASW, CEU, LWK, MEX and YRI population 
groups.  
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SNP rs20577 represented as alleles G and A, with G being the ancestral allel, was 
present in high frequencies among population groups ASW, CHD, GIH, LWK, MKK, 
YRI implying only a 26%, 2%, 1%, 26%, 11% and 32% of the occurrence of the 
minor A allele respectively. However, the minor allele of the same SNP was observed 
to be present in 100% of the CEU, CHB and JPT population samples, implying the 
potential influence of this SNP in the binding of the CP2/LBP-1c/LSF transcription 
factors to their corresponding TFBS.  
 
SNP rs12928665, present in all 11 population groups was observed on average in 
68% of the population samples in the form of its ancestral allele (i.e. A) which 
corresponds to the TFBS configuration of the CDP transcription factor. The minor G 
allele was present in an average of 31% of the cases that this SNP occurred on the 
CIITA gene among all population samples.  
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4.4 Summary 
 
Beginning with the collection of 121 SNPs found to overlap with TFBSs in chapter 3 
(Appendix I-I), this chapter focused on the observation of any one of these SNPs 
among the 11 population groups defined by the International HapMap project. To do 
this, SNP genotype data was obtained from the HapMap Genome Browser tool with a 
custom program read_hapmap.pl (Appendix II-A). Subsequent to this, a custom 
program filter_hapmap.py filtered this data for the identification of SNPs (from the 
original list of 121) that were present within one or more of the 11 population groups. 
This resulted in the identification of 3 novel SNPs with potential phenotypic effect 
associated with 5, 9 and 11 population groups respectively.  
 
SNP rs12928665, occurring within the CIITA gene, was found to be present in all 
population groups, with a higher percentage of the ancestral allele (A) being present 
in 7 of the 11 population groups, when compared to the presence of the minor allele 
(G). Population groups ASW, CEU, GIH, LWK, MEX, MKK, TSI and YRI indicated 
higher percentages of the ancestral allele (A), whereas CHB, CHD and JPT indicated 
higher percentages of the presence of the minor allele (G).  
 
SNP rs20577, occurring within the TNFRSF10A gene, was found to be present in 9 
population groups. Population groups ASW, CHD, GIH, LWK, MKK and YRI 
indicated higher percentages of the ancestral allele (G), whereas CEU, CHB and JPT 
indicated a 100% possibility of the minor allele (A) being present. This may imply 
that the binding of the CP2/LBP-1c/LSF transcription factors to their corresponding 
TFBSs may potentially be altered/influenced by the change in its TFBS nucleotide 
base configuration in the CEU, CHB and JPT population groups through the 
occurrence of the rs20577 SNP within the putative binding site of the CP2/LBP-
1c/LSF transcription factors.  
 
SNP rs4150842, occurring within the promoter region of the E2F5 gene, was found to 
be present in 5 population samples. Population groups ASW, CEU, LWK, MEX and 
YRI were found to have higher percentages of the ancestral allele (C), with 
percentages of 3% or lower of the minor allele (T) present.  
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This may indicate that in 97% of the instances that the rs4150842 SNP occurs within 
the E2F5 gene, the C/EBP transcription factor would bind to its corresponding 
(unaltered) TFBS whereas in only 3% or less of these occurrences it may potentially 
be influenced by the change in its TFBS nucleotide base configuration in these 5 
population groups. 
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CHAPTER 5 
 
 
Discussion 
 
 
THE potential of a diagnostic marker that can be measured in blood is a high priority 
in view of the profuse amounts of patients that have been diagnosed with ovarian 
cancer all too late. Although promising markers have been reported in the last decade 
to contribute to this target (e.g. CA125, etc.) the use of these markers to detect 
ovarian cancer early enough to reduce mortality rates remains a challenge since these 
screening methods must be able to identify the cancer before it becomes invasive, i.e. 
early enough for the disease to be curable (Coukos et al., 2008). Until now, only the 
CA125 assay has been able to detect ovarian cancer before symptoms arise (Coukos 
et al., 2008) but with a high rate of false positive predictions (Vuillez et al., 1997; 
McIntosh et al., 2004 & Mahata, 2006).  
 
The focus of this study was to identify SNPs that may have a potential to influence 
the expression of genes implicated in ovarian cancer. To do this, an original collection 
of 379 candidate genes were isolated from the Dragon Database for the Exploration of 
Ovarian Cancer Genes (DDOC), and their chromosomal distributions elucidated and 
mapped. The three highest concentrations of candidate genes were found to be located 
on chromosomes 1, 11 and 19, stimulating the assumption that these chromosomes 
are candidates to investigate for potential female-specific diseases. Chapter 3 (Figure 
3.11) also presents the techniques whereby the candidate genes were experimentally 
proven, with the majority of the genes being proven via RT-PCR, western blotting 
and immunohistochemistry; wet-laboratory based techniques that have been 
implemented and practiced widely in the elucidation of molecular data.  
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From the 379 candidate genes studied, a total of 10863 SNPs were identified through 
the application of three SNP annotation tools. These SNPs constituted the total 
number of SNPs identified within the specific promoter regions analyzed by each 
SNP annotation tool, based on the criteria described in Sections 3.2.2.1, 3.2.2.2 and 
3.2.2.3 of this study. A large difference in the number of SNPs obtained from each of 
the SNP annotation tools was observed, with 97% of the SNPs arising from the 
SNP@Promoter tool as illustrated in Figure 3.13. This was the result of the inclusion 
of all SNP results obtained from the SNP@Promoter tool within the 5kb upstream 
and downstream regions of all genes, whereas SNPs included from the F-SNP and 
PupaSuite tools only constituted those present within regulatory regions of the same 
promoter region or putative TFBSs (defined by Jaspar and Transfac position weight 
matrices) in the 5kb upstream promoter region of all genes, respectively (Figures 3.14 
and 3.15).  
 
Furthermore, the SNP results depicted above indicated higher SNP densities for the 
HLA-DRB1, HLA-DQA1, HBB, BAGE, TUSC3, IL6 and CSF2 genes (Figures 3.13, 
3.14 and 3.15). The HLA genes are important in helping the immune system in 
distinguishing the body's own proteins from proteins made by foreign invaders such 
as viruses and bacteria (Genetics Home Reference, 2009). They are highly 
polymorphic (Pénzes et al., 1999), and the HLA region has also been associated with 
genetic predisposition to diseases in Asian populations (Bouma et al., 1997 & Keicho 
et al., 1998). The HBB gene, located on chromosome 11, alongside HBA is responsible 
for normal adult haemoglobin structure, and mutations in this gene have been 
associated with diseases such as sickle-cell anemia and thallasemia (National Centre 
for Biotechnology Information, 2009).  
 
BAGE is a gene located on chromosome 21 that codes for a the tumor antigen protein 
that are recognized by lymphocytes (National Centre for Biotechnology Information, 
2009), which stimulates the body's immune system to find and eradicate cancer cells 
(National Centre for Biotechnology Information, 2009).  
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TUSC3 is a candidate tumor suppressor gene found on chromosome 8, while the IL6 
(chromosome 7) gene encodes a cytokine that functions in the inflammation and the 
maturation of B cells. CSF2 found on chromosome 5 is responsible for the control of 
production, differentiation and function of granulocytes and macrophages (National 
Centre for Biotechnology Information, 2009), thereby playing a vital role in cellular 
health. 
 
From the list of 10863 SNPs mapped to the original 379 candidate genes, 10773 were 
verified via comparison with SNPs catalogued in the dbSNP database (Build 129), to 
eradicate false positive SNP predictions that may have been reported by any of the 
three SNP annotation tools employed in sections 3.2.2.1-3.2.2.3 of this study. The 
dbSNP database has provided this study with an accurate grouping of SNPs to be 
compared with TFBS predictions obtained from the MATCHTM tool (Figure 3.16).  
 
To predict TFBSs present within the ovarian cancer related genes, promoter regions 
classified as the 2000bp upstream and 500bp downstream regions of all TSSs present 
on each of the 379 candidate genes, were extracted and queried through the 
MATCHTM tool. This was done as most putative regulatory regions are identified 
within the promoter regions of genes (Hunninghake et al., 1989; Ahlgren et al., 1990; 
Horie et al., 1996 & Savon et al., 1997).  
 
A total of 6796 high quality TFBSs (i.e. high core similarity and matrix match scores) 
were mapped to 1155 promoter regions on all 379 genes, with the highest 
concentration of TFBSs identified within the upstream regions of 200bp to 1400bp of 
the TSSs for the candidate gene data set as described by Figure 3.17. This suggested 
that the maximum numbers of TFBSs were included in the specified promoter region 
of 2000bp upstream and 500bp downstream regions (as classified by this study). The 
approach of the analyses utilized several custom programs for data handling and 
integration, facilitated by published, highly utilized databases and tools. This has led 
to the creation of a workflow on which SNPs with potential phenotypic effect may 
be elucidated in search of potential ovarian cancer biomarkers.   
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While, many biomarker studies have been unsuccessful as a result of variation within 
individuals' tissue localisations (Naylor, 2003 & Mayeux, 2007) as well as between 
individuals within a population (Nielsen et al., 2005), utilizing SNP annotation 
technologies and prediction of SNPs within regulatory sequences of genes associated 
with ovarian cancer provides scientists with new potential therapeutic targets in 
response to the disease.  
 
The SNP patterns that influence function may reflect common haplotypes in a 
population suggesting that there may exist functionally significant interaction between 
SNPs and regulatory regions according to the haplotype context (Chen et al., 2001). 
 
Chapter 4 aimed to identify SNP biomarkers present within several population 
groups defined by the International HapMap consortium. In doing so, a custom 
program designed to extract SNP genotype data was created and applied to all 
candidate genes. This resulted in the identification of 23852 common SNPs present on 
the forward strands of these genes in all 11 of the population groups, and 24133 
common SNPs identified on the reverse strands. The reason for the great difference in 
the numbers of SNPs between the data collected by the HapMap Genome Browser 
and the SNP annotation tools applied in chapter 3, is that the SNP prediction tools 
analyzed specified promoter regions, whereas the HapMap project provides SNP 
predictions across the entire sequence length of the gene.  
 
From the 121 SNPs found to overlap with TFBSs in chapter 3, only three were 
identified among these 11 population groups. Despite the absence of 198 SNPs in the 
HapMap data set, these SNPs are not considered as any less important to the 
phenotypic expression of ovarian cancer and may be investigated in future work.  
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SNPs rs4150842, rs20577 and rs12928665 identified on genes E2F5, TNFRSF10A and 
CIITA genes, were found to occur in 5, 9 and 11 population groups respectively. 
Because these are not limited to a specific population group, they may be broadly 
applicable as potential markers for ovarian cancer, when compared to the targeting of 
SNPs that are present in only one or two population groups. This observation 
however, excludes the predisposition of smaller population groups that may possess 
biomarkers or SNPs that may be implicated or linked to ovarian cancer but not 
represented in the HapMap project data set or represented in lower frequencies.  
 
The tumor necrosis factor receptor (TNFRSF10A) gene, belonging to the superfamily 
A (member 10) encodes for the death receptor 4 protein that mediates apoptosis. The 
regulatory region of the TNFRSF10A gene has been shown to reside in a conserved 
region of cysteine-rich domain, resulting in the development of prostate cancer when 
compromised via SNP rs20576 (Langsenlehner et al., 2008). The putative TFBS 
undergoes a change from its original compilation including a guanine base to one of 
that including an adenine nucleotide base in this case.  
 
In chapter 4 of this study it was shown that the rs20577 SNP within the same gene 
present as the ancestral allele (G) occurred in higher frequencies in the ASW, CHD, 
GIH, LWK, MKK and YRI population groups. This implies that the putative TFBS 
nucleotide base (coinciding with rs20577) constituting the G allele is less likely to be 
present as the minor allele (A) in these population groups. Alternatively, population 
groups CEU, CHB and JPT were shown to possess the minor allele (A) 100% of the 
instances that it occurred in these population samples, indicating the potential loss of 
the putative nucleotide base (G) on the TNFRSF10A gene. This change potentially 
influences the binding of the CP2 or LBP-1c or LSF transcription factors to their 
putative TFBSs on this gene. The presence of the minor allele (A) in these population 
groups corresponds to the Utah residents with Northern and Western European 
ancestry, Han Chinese in Beijing and Japanese in Tokyo population groups 
respectively. This suggests that the presence of this allele is specifically associated to 
these population groups. The CP2 or LBP-1c or LSF transcription factors also known 
as alpha-CP2, alpha CP2a, Late SV40 factor or SEF, has been shown to play a part in 
the activation of the SV40 late promoter transcription process (Lambert et al., 2000). 
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Moreover, it has been reported to influence the risk of Alzheimer's disease (Lambert 
et al., 2000). The presence and/or influence of the rs20577 SNP on this gene implies 
that the death receptor 4 protein, encoded by the TNFRSF10A gene may be rendered 
dysfunctional/altered in some way and potentially result in the onset or progression of 
ovarian cancer, affecting the role/s of the CP2/LBP-1c/LSF transcription factors. 
 
The Class II transactivator (CIITA) gene plays a role in regulating cellular immune 
recognition (van der Stoep et al., 2002). Inactivation or interferences with CIITA 
regulation has been closely associated with the absence of HLA-DR induction, 
implying that the body is unable to distinguish between its own proteins and those of 
foreign invaders (Satoh et al., 2004). Chapter 4 of this study highlights the 
occurrences of the A/G alleles introduced by the rs12928665 SNP on the promoter 
region of this gene, indicating a higher prevalence of the ancestral allele (A) in 
population groups ASW, CEU, GIH, LWK, MEX, MKK, TSI and YRI. Alternatively, 
population groups CHB, CHD and JPT showed a higher presence of the minor allele 
(G), indicating the potential influence of the CDP transcription factor binding to its 
putative TFBS on this gene. The presence of the minor allele (G) in these population 
groups corresponds to the Han Chinese in Beijing, Chinese in Metropolitan Denver 
and Japanese in Tokyo population groups respectively. This suggests that the 
presence of this allele is specifically associated to the population class that may be 
categorized as those from Eastern/Southern Asian decent.  
 
The CCAAT displacement protein (CDP) is a repressor protein that has been 
observed to interact with the special AT-rich sequence binding protein 1 (SATB1) 
(Liu et al., 1999). These proteins have been reported to potentially be regulated by 
each other via protein-protein interaction (Liu et al., 1999), suggesting the loss of 
regulatory control be either one in the absence of the other. The high incidences of the 
minor allele (G) if SNP rs12928665 located in the promoter region of the CIITA gene 
in population groups CHB, CHD and JPT may influence the binding between the 
CDP transcription factor and its putative TFBS, implicating the protein-protein 
interaction between the SATB1 and CDP molecules. The consequences of this 
hypothetical observation on the progression or pathogenesis of ovarian cancer may 
only be determined by the experimental testing of each of these scenarios.  
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The E2F genes (E2F1, E2F3 and E2F5) have been documented in retinoblastoma, 
bladder, lung, ovarian and prostate cancers (Johnson et al., 2006). The protein 
encoded by the E2F5 gene plays a crucial role in the control of cell cycle and action of 
tumor suppressor proteins (Reimer et al., 2006). This protein is differentially 
phosphorylated and is expressed in a wide variety of human tissues (GeneCards, 
2009). Chapter 4 of this study illustrated the presence of the C and T alleles of SNP 
rs4150842 occurring within the regulatory regions of the E2F5 gene. These alleles 
indicate a change from the ancestral allele (G), which suggests the potential influence 
of the binding of the C/EBP transcription factor to its putative TFBS on this gene.  
 
The CCAAT enhancer-binding protein (C/EBP) is composed of 5 subfamilies of TFs 
(i.e. C/EBPdelta, C/EBPbeta, C/EBPalpha, C/EBPepsilon and C/EBPgamma), each 
with their own individual sets of interacting factors. More precisely the C/EBP 
molecule has been shown to interact with approximately 26 other factors, forming ± 
three protein complexes with a few of these factors (Yang et al., 2003). Regulated by 
glucose and insulin, this gene has been characterized as a putative insulin-responsive 
element in the rat genome (Maytin et al., 1999; Chen et al., 2001 & Sugiyama et al., 
2001). Moreover, the occurrence of SNP rs4150842 on the E2F5 gene that potentially 
affects the binding of the C/EBP molecule, may subsequently implicate the 
functionalities of these 26 other interacting factors in the expression profile of the 
E2F5 gene.  
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CHAPTER 6 
 
 
Conclusions 
 
 
THE most promising approach to the reduction of mortality rates for ovarian cancer is 
through the early intervention of the disease. This will require the identification of a 
screening test that is able to detect the disease through the presence of a precursor 
within high-risk women before it is able to become invasive. This approach would 
ensure the reduction of disease incidence rates and increase of survival rates for those 
affected. Although SNP pattern recognition (i.e. SNP profiling) may not serve as a 
sole solution for the prognosis of high-risk women, it may be recognized that 
collaboration of this technique with existing ones may be required to identify and 
validate a more efficient diagnostic and early detection method (Coukos et al., 2008).  
 
This study has demonstrated the use of a simple protocol for the identification of 
SNPs that potentially affect transcription factor binding. These SNPs could be the 
causal factors for changes in the expression profile of genes. While this protocol 
illustrates a computational and scalable approach to the identification of SNPs related 
to diseases, it has in addition generated notable findings.  
 
The combined application of approaches in this study has identified three SNPs (i.e. 
rs4150842, rs20577 & rs12928665) among genes TNFRSF10A, CIITA and E2F5 that 
may be useful as diagnostic markers for the potential early detection of ovarian 
cancer. These SNPs and their associated implications on gene expression however, 
require experimental validation through the potential application of SNP microarrays. 
SNP microarrays are designed to genotype SNPs, capable of reporting hybridization 
of DNA fragments and therefore can be used for the purpose of detecting genomic 
fragments (McCann et al., 2007).  
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The use of SNP arrays will be of great value to the ongoing search for ovarian cancer 
biomarkers if these SNPs are experimentally shown to be causal factors in the 
phenotypic expression of ovarian cancer, they could be considered as additive test 
measures (i.e. be coupled to existing ovarian cancer prognosis techniques, such as the 
CA125 assay). This may provide a plausible prognosis technique to many high-risk 
women. 
 
The use of SNPs as early detection or susceptibility biomarkers for the prognosis of 
ovarian cancer has great potential in both diagnosing and strategizing the most 
optimal treatment plan for the disease. Because there are an estimated 3 billion SNPs 
along the human genome and are evolutionarily conserved, they are easy to follow in 
population studies and have attracted the attention of pharmaceutical companies with 
their potentially huge financial prospects (Nomikos, 2006). 
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Future Directions 
 
 
SCREENING for ovarian cancer risk markers may be an important objective to explore 
in future work, because of the many challenges to early detection of curable invasive 
tumors. One of the aspects to be addressed in future work is the reduction of mortality 
rates from ovarian cancer and increase in cure rates by any number of feasible 
measures.  
 
Following the results obtained from this study, the focus of future work should 
include the experimental validation of SNPs rs12928665, rs20577 and rs4150842, and 
their overlapping with the putative TFBSs to which the transcription factors CDP, 
CP2/LBP-1c/LSF and C/EBP bind. 
 
Furthermore, the effects of these SNPs coinciding with TFBSs on genes E2F5, 
TNFRSF10A and CIITA should be investigated experimentally, to determine the 
potential influence on post-operative drug efficacy and/or drug resistance caused by 
the loss or gain of transcription factors that may bind to or form complexes with post-
operative ovarian cancer drugs. These results may suggest how SNPs occurring 
within TFBSs (potentially influencing the binding of TFs) affect progression, 
regression or susceptibility of/for ovarian cancer.  
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Appendix I 
 
A. Ovarian Cancer Candidate Gene Data Set 
 
HUGO Gene Symbols 
ABCB1 BCL2L1 CDKN1C DLEC1 FLT1 KLF2 MDM2 PCSK6 SPINK1 
ABCB11 BCPR CDKN2A DLX4 FN1 KLF6 MEN1 PDGFRA SPINT2 
ABCG2 BECN1 CDKN2B DNAJC15 FOLR1 KLK10 MKI67 PEBP4 SR-A1 
ACHE BIRC2 CDKN2C DNMT1 FOXP3 KLK11 MLH1 PIK3CA SST 
ACVR1B BIRC4 CDKN2D DNMT3B FRA9E KLK13 MLLT4 PLA2G4C ST8 
ACVR1C BMP2 CDR1 DPH1 FRAP1 KLK14 MMP1 PLAGL1 STAT3 
ACVR2A BMP4 CDR2 DPYD FSHR KLK15 MMP14 PLAT STEAP1 
ACVR2B BRAF CDX2 DUSP3 GADD45A KLK3 MMP2 PLAU STK11 
ADM BRCA1 CFLAR E2F1 GALT KLK4 MMP26 PLAUR TACSTD1 
AES BRCA2 CGB5 E2F2 GAS6 KLK5 MMP3 PPAP2A TBX3 
AGPAT2 BRIP1 CHEK2 E2F3 GJA1 KLK6 MMP7 PPARG TERC 
AGTR1 BRMS1 CIITA E2F4 GJB2 KLK7 MMP8 PPP2R4 TERT 
AKAP13 C11orf30 CLDN1 E2F5 GNRH1 KLK8 MMP9 PPP2R5D TFAP2A 
AKT1 C1orf38 CLDN3 EBAG9 GPC1 KLK9 MPG PRKACA THBS3 
AKT2 CALCA CLDN4 ECGF1 GPLD1 KRAS MPO PRKCI TMSB10 
AMH CAMK4 CLIP1 EDG4 GPR68 KRAS1P MS4A1 PSD3 TNF 
AMPH CASP3 COL18A1 EDG7 GRN LAMP1 MSH2 PTEN TNFRSF10A 
APOA1 CAV1 COMT EDN1 GSK3B LASP1 MSH3 PTGS1 TNFRSF10B 
APOE CBR3 CSAG2 EDNRA GSTM1 LATS1 MSH6 PTK2 TNFSF10 
 
  Continued… 
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HUGO Gene Symbols 
AR CCND1 CSF1 EEF1A2 GSTO2 LCFS2 MSLN PTP4A3 TOC 
ARID4B CD24 CSF1R EGF GSTP1 LGALS1 MSN PYGO2 TOP2A 
ARMCX1 CD34 CSF2 EGFR HBB LOH11CR2A MSR1 RAB25 TP53 
ARMCX2 CD40 CSF3 EIF5A2 HGF LTBP1 MSX1 RAF1 TP73L 
ARMCX3 CD44 CSF3R EPHA1 HIF1A LUZP4 MTHFR RASSF1 TTR 
ATF3 CD46 CSK EPHA2 HLA-DQA1 LZTS1 MUC1 RBP1 TUBB3 
ATM CD47 CTAG1B EPHA5 HLA-DRB1 MAD2L1 MUC16 RNASE2 TUSC3 
ATP7A CD63 CTAG2 EPHB2 HMGA1 MAGEA1 MUC2 RNASET2 TYMS 
ATP7B CD80 CTNNA1 EPHB4 HOXA9 MAGEA4 MUC3A ROCK1 UTRN 
ATR CD82 CTNNB1 EPHX1 HRAS MAP2K1 MUC4 RPS6KB1 VEGFA 
AURKA CD86 CTSB EPO HSPB1 MAP2K3 MUC5AC RSF1 VTCN1 
AXIN2 CD9 CTSD EPOR HTRA1 MAP2K4 MVP SDC1 WNT2B 
B2M CD99 CTSL ERBB2 IGF2 MAP2K7 MYC SELENBP1 WWOX 
BACH1 CDC20 CXADR ERBB3 IGFBP3 MAP3K1 MYCL1 SEMA3B XPA 
BACH2 CDC25A CXCL1 ERBB4 IL13RA2 MAP3K2 MYO18B SERPINB5 XRCC1 
BAD CDC25B CXCL12 ERCC1 IL18 MAP3K3 NBN SERPINE1 XRCC2 
BAG1 CDC25C CXCR4 ERCC2 IL6 MAP3K4 NBR1 SERPINF1  
BAGE CDC42 CYP1B1 ERCC3 ILK MAP3K5 NCOA3 SHMT1  
BAK1 CDH1 CYP3A4 ERCC5 INSR MAP3K8 NEO1 SLC2A1  
BARD1 CDH13 DAB2 ETS1 ITGB3 MAPK1 NTRK2 SMAD4  
BARX2 CDK2 DCC FASLG KDR MAPK3 OPCML SNCG  
BAX CDK4 DDR1 FASN KISS1 MAPK8 OVCA2 SOD2  
BCHE CDKN1A DIRAS3 FBXW7 KIT MCAM PARK2 SPARC  
BCL2 CDKN1B DLC1 FILIP1L KITLG MCC PAX8 SPDEF  
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B. html_read.py 
 
This program reads through multiple HTML files stored in a single working directory and 
extracts SNP results that are displayed in table format within each HTML webpage. 
Using the python table_parser module, this program was designed to extract the RefSNP 
ID, chromosomal location, strand orientation (i.e. forward or reverse) and nucleotide base 
position of each SNP result per gene and write these results into a single comma 
delimited output file (Figure 3.8, File 3). 
 
#!/usr/bin/env python 
 
import csv, os 
from table_parser import * 
 
#----------Accesses folder that stores all SNP@Promoter result files----------#  
path = "/Users/kavisharamdayal/SNP@Promoter_Results" 
snp_prom = os.listdir(path) 
writer = csv.writer(file('SNP@Promoter.csv', 'w')) 
#----------Selects gene symbol from SNP@Promoter result file name----------# 
def get_genename(f): 
    gene = str(f).split("\'")[1].split(".")[0] 
    return gene 
 
def get_info(line): 
    strand = "" 
    if line[1].startswith("SNP"): 
        return "" 
    elif line[1].startswith("Allele"): 
        return "" 
    elif line[1].startswith("NM"): 
        return "" 
    else: 
#----------Return SNP info----------# 
        snp = 'rs'+str(line[1]) 
        chr = line[2].split(":")[0].split("r")[1] 
        pos = line[2].split("(")[1].split(",")[0] 
        if len(line) >= 10: 
            strand = line[4] 
        else: 
            strand = " " 
    return snp, chr, strand, pos 
#----------Reads through all files in directory----------#  
for file in snp_prom: 
    if file.endswith(".html"): 
        f = open(file,"rb") 
#----------Extract and read tables from HTML file----------#  
        p = TableParser() 
        p.feed(f.read()) 
#----------Reads through first table in HTML file----------#  
        for line in p.doc[0]: 
#----------Writes column containing RefSNPs if not a header----------#  
            if get_info(line) != "": 
                a,b,c,d = get_info(line) 
                writer.writerow([get_genename(f),a,b,c,d]) 
f.close() 
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C. pupasuite_read.py 
 
This program reads through Transfac and Jaspar result files (flat files) obtained from the 
completion of a batch query of candidate genes through the PupaSuite SNP annotation 
tool (Section 3.2.2.3). The program then reads through SNP results per gene, converting 
the Entrez gene IDs into HUGO gene symbols (for consistency & comparability). All SNP 
results (Transfac and Jaspar) per gene were then written to a single comma delimited 
output file (Figure 3.8, File 4).  
 
#!/usr/bin/python 
 
import csv 
 
f = open("transfac.txt","rb") 
g = open("jaspar.txt","rb") 
h = open("IDconverterResults73486.csv","rb") 
writer = csv.writer(file('PupaSuite.csv', 'w')) 
ens = "" 
dict = {} 
 
#----------Convert Ensembl IDs to Gene Symbol----------# 
def get_genename(): 
    for l in h.readlines(): 
        temp = l.rstrip().split(",")[1].rstrip() 
        dict[temp] = l.rstrip().split(",")[0] 
    return dict 
 
#----------Compile Transfac Results----------# 
for j in f.readlines(): 
    if j.startswith("rs"): 
        snp = j.rstrip().split()[0] 
        ens = j.rstrip().split()[1] 
        gene = get_genename()[ens] 
        writer.writerow([gene,snp]) 
 
#----------Compile Jaspar Results----------# 
for k in g.readlines(): 
    if k.startswith("rs"): 
        snp = k.rstrip().split()[0] 
        ens = k.rstrip().split()[1] 
        gene = get_genename()[ens] 
        writer.writerow([gene,snp]) 
 
f.close() 
g.close() 
h.close() 
 
 
 
 
 
 
 
 
 
 
 111 
D. all_snps.py 
 
This program reads through the three result files obtained from each SNP annotation tool 
(Figure 3.8, Files 2, 3 & 4) and compiles all SNP results into a single comma delimited 
file, while collating SNP results in order of "HUGO gene symbol", "RefSNP ID", 
"Chromosomal location", "Strand orientation" and "Nucleotide base position". 
 
#!/usr/bin/python 
 
import csv 
 
f = open("F-SNP_Results.csv","rb") 
g = open("SNP@Promoter_Results.csv","rb") 
h = open("PupaSuite_Results.csv","rb") 
writer = csv.writer(file('All_SNPs.csv', 'w')) 
count = 0 
 
#----------Compile F-SNP Results----------# 
for line in f.readlines(): 
    gene = line.rstrip().split(",")[0] 
    snp = line.rstrip().split(",")[1] 
    chr = line.rstrip().split(",")[2]     
    strand = line.rstrip().split(",")[3] 
    pos = line.rstrip().split(",")[4]     
    writer.writerow([gene,snp,chr,strand,pos]) 
 
#----------Compile SNP@Promoter Results----------# 
for line in g.readlines(): 
    gene = line.rstrip().split(",")[0] 
    snp = line.rstrip().split(",")[1] 
    chr = line.rstrip().split(",")[2] 
    strand = line.rstrip().split(",")[3] 
    pos = line.rstrip().split(",")[4] 
    writer.writerow([gene,snp,chr,strand,pos]) 
 
#----------Crosscheck PupaSuite Results----------# 
for line in h.readlines(): 
    gene = line.rstrip().split(",")[0] 
    snp = line.rstrip().split(",")[1] 
    i =open("SNP_Ref.csv","rb") 
    for k in i.readlines(): 
        gn = k.rstrip().split(",")[0] 
        sn = k.rstrip().split(",")[1] 
        if gene==gn and snp==sn: 
            print "Match",count,":",gn,sn 
            count +=1 
        # Total confirmed SNPs= 42 {Total PupaSuite SNPs = 90} 
         
f.close() 
g.close() 
h.close() 
i.close() 
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E. verify_snps.py 
 
This program reads through the accumulated SNP results (Figure 3.8, File 5) obtained 
from the custom program all_snps.py (Appendix I-D) and the result flat file from querying 
all RefSNP IDs listed in File 5 (Figure 3.8) through the dbSNP database. The program 
then searches for SNPs that are listed in both files. All SNPs from the accumulated SNP 
results (Figure 3.8, File 5) that were present in the dbSNP result file (i.e. present in 
dbSNP Build 129) were classified as verified SNPs and output to a single comma 
delimited file (Figure 3.8, File 6). 
 
#!/usr/bin/python 
 
import csv 
dbSNPs = [] 
count1 = 0 
count2 = 0 
 
f = open("All_SNPs.csv","rb") 
g = open("dbSNP_BATCH_Results.txt","rb") 
writer = csv.writer(file('SNP_Ref.csv', 'w')) 
 
#----------Create dbSNP list of query SNPs----------# 
for line in g.readlines(): 
    if line.startswith("rs"): 
        dbSNPs.append(line.rstrip().split()[0]) 
 
#----------Verify all predicted SNPs & create SNP reference table----------# 
for line in f.readlines(): 
    if line.rstrip().split(",")[1] in dbSNPs: 
        writer.writerow([line.rstrip()]) 
        count1 += 1 
    else: 
        count2 += 1 
 
# print "Verified:",count1 = 10640 
# print "Unverified:",count2 = 133 
 
f.close() 
g.close() 
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F. label_promoters.py 
 
This program was created for the relabeling of all promoter sequences that were 
retrieved by the Promex tool. Since Entrez IDs of all candidate genes were queried 
through the Promex tool, the resulting promoter regions were labeled according to these 
Entrez IDs instead of the HUGO gene symbols, as with all other results in this study. This 
program read through the Promex result file (Figure 3.8, File 7) and renamed the 
promoter sequences in the following order: “HUGO gene symbol”, “Strand orientation”, 
“Chromosomal location”, “Nucleotide base start position” and “Nucleotide base stop 
position”. 
 
#!/usr/bin/python 
 
import csv 
 
ids = {} 
f = open("Gene_Entrez_IDS.csv","rb") 
g = open("Promex_Promoter_Regions[-2000,+500].txt","rb") 
 
#----------Extract & store Entrez IDs in directory----------# 
for line in f.readlines(): 
    ids[line.split(",")[1].rstrip()] = line.split(",")[0] 
     
#-------Convert Entrez IDs to Gene Symbols & compile sequence details-------# 
for line in g.readlines(): 
    if line.startswith(">"): 
        entrez_id = line.split(",")[0].split()[2] 
        chr = line.split(",")[3].split()[1] 
        strand = line.split(",")[4].split()[1].rstrip() 
        seq_start = line.split(",")[6].split()[1] 
        seq_stop = line.split(",")[7].split()[1] 
        new_label = 
str(">"+ids[entrez_id])+str(":"+strand)+str(":"+chr)+str(":START,"+seq_start)+str(":STOP,"
+seq_stop) 
        print new_label 
    else: 
        print line.rstrip() 
     
f.close() 
g.close() 
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G. match_read.py 
 
This program reads through the results obtained from the MATCH
TM
 tool and creates a 
TFBS reference table containing the following fields of information: “HUGO gene 
symbol”, “Strand orientation”, “Chromosomal location”, “TFBS Start & Stop nucleotide 
base positions”, “Transcription factor”, “Core Similarity Score”, “Matrix Similarity Score”, 
“Transcription factor nucleotide sequence” and “Matrix identifier”. The script identifies 
TFBS nucleotide base positions per promoter sequence based on the length of the 
transcription factor identified and the start and end positions (bp) of the promoter 
sequence that was queried, e.g. if a transcription factor of length 8bp was identified on a 
specific promoter sequence, the TFBS range was calculated as follows: 
 
For transcription factors (TF) predicted on the forward strand: 
TFBS Start (bp) = Promoter start position (bp) (obtained from promoter 
sequence label (Figure 3.8, File 7)) + TF (MATCH
TM
) nucleotide base position  
 
TFBS Stop (bp) = Promoter start position (bp) (obtained from promoter 
sequence label (Figure 3.8, File 7)) + length of TF (bp) - 1 
 
For transcription factors (TF) predicted on the reverse strand: 
TFBS Start (bp) = Promoter end position (bp) (obtained from promoter sequence 
label (Figure 3.8, File 7)) - TF (MATCH
TM
) nucleotide base position 
 
TFBS Stop (bp) = Promoter end position (bp) (obtained from promoter sequence 
label (Figure 3.8, File 7)) - length of TF (bp) - 1 
 
#!/usr/bin/python 
 
import csv 
 
f = open("MATCH_Promex(-2000+500)_Results.csv","rb") 
writer = csv.writer(file('TFBS_Ref.csv', 'w')) 
tf = "" 
gene = "" 
chr = "" 
 
#----------Filter through MATCH
TM
 results----------# 
for l in f.readlines(): 
    line = l.split() 
    temp = line 
    for j in temp: 
 
#----------Identify results for each promoter region----------# 
        if "Scanning" in j: 
            gene = temp[3].split(":")[0] 
            strand = temp[3].split(":")[1] 
            chr = temp[3].split(":")[2] 
            seq_start = int(temp[3].split(",")[1].split(":")[0]) 
            seq_stop = int(temp[3].split(",")[2][:-1]) 
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#------Compile results for each transcription factor predicted on the fwd strand------# 
        elif (j.startswith("V$")) and temp[2] == "(+)": 
            tf = temp[6] 
            fam = temp[0] 
            tfbs_start = seq_start+int(temp[1]) 
            tfbs_stop = tfbs_start+int(len(temp[5])) 
            tfbs = str(tfbs_start)+"-"+str(tfbs_stop) 
            css = temp[3] 
            mss = temp[4] 
            tf_seq = temp[5] 
            writer.writerow([gene,strand,chr,tfbs,tf,css,mss, tf_seq,fam]) 
 
#-------Compile results for each transcription factor predicted on the rev strand------# 
        elif (j.startswith("V$")) and temp[2] == "(-)": 
            tf = temp[6] 
            fam = temp[0] 
            tfbs_start = seq_stop-int(temp[1]) 
            tfbs_stop = tfbs_start-int(len(temp[5])) 
            tfbs = str(tfbs_stop)+"-"+str(tfbs_start) 
            css = temp[3] 
            mss = temp[4] 
            tf_seq = temp[5] 
            writer.writerow([gene,strand,chr,tfbs,tf,css,mss, tf_seq,fam]) 
         
f.close() 
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H. overlaps.py 
 
This program compares the SNP results stored in the SNP reference table (Figure 3.8, 
File 6) to the TFBS results stored in the TFBS reference table (Figure 3.8, File 9). The 
program first isolates the HUGO gene symbol, RefSNP ID, Strand orientation, 
Chromosomal location and Nucleotide base position of all entries within the SNP 
reference table and stores this information in a dictionary with the nucleotide base 
position as the key and remaing information as values. The program then isolates the 
HUGO gene symbol, Strand orientation, Chromosomal location, TFBS start position, 
TFBS end position, Transcription factor, Matrix identifier, Transcription factor nucleotide 
sequence, Core similarity score and Matrix similarity score for each entry within the 
TFBS reference table. For each SNP result in the dictionary created above, the script 
then checked (for each result in the TFBS reference table) if (1) the SNP was located at 
or between the TFBS start and end nucleotide base positions, (2) the strand orientations 
were the same, and (3) chromosomal locations were the same. All SNPs that satisfied 
these criteria were classified as SNPs coinciding with TFBSs and written to an output 
comma delimited file (Figure 3.8, File 10).  
 
#!/usr/bin/python 
 
import csv 
 
sref = open("SNP_Ref.csv","rb") 
tref = open("TFBS_Ref.csv","rb") 
writer = csv.writer(file('SNPs_within_TFBSs.csv', 'w')) 
dict = {} 
genes = [] 
count = 0 
 
#----------Open SNP reference table & store info in directory----------# 
for j in sref.readlines(): 
    gene1 = j.rstrip().split(",")[0] 
    snp = j.rstrip().split(",")[1] 
    strand1 = j.rstrip().split(",")[3] 
    chr1 = j.rstrip().split(",")[2] 
    pos1 = int(j.rstrip().split(",")[4].split('\"')[0]) 
    dict[pos1]=([gene1,snp,strand1,chr1,pos1]) 
writer.writerow(["Gene","SNP","Strand","Chromosome","Position","TF","Matrix 
Identifier","TF Sequence","CSS","MSS"]) 
 
#----------Open TFBS reference table & store info in temporary variables----------# 
for k in tref.readlines(): 
    gene2 = k.rstrip().split(",")[0] 
    strand2 = k.rstrip().split(",")[1] 
    chr2 = k.rstrip().split(",")[2].split("r")[1] 
    s_pos = int(k.rstrip().split(",")[3].split("-")[0]) 
    e_pos = int(k.rstrip().split(",")[3].split("-")[1])-1 
    tf = k.rstrip().split(",")[4] 
    css = k.rstrip().split(",")[5] 
    mss = k.rstrip().split(",")[6] 
    fam = k.rstrip().split(",")[8] 
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#----------Compare SNP & TFBS strand orientation, chromosome & nucleotide base 
positions for coinciding pairs----------# 
    for i in dict: 
        strand1 = dict[i][2] 
        chr1 = dict[i][3] 
        if (i >= s_pos) and (i <= e_pos) and (strand1 == strand2) and (chr1 == chr2): 
            if dict[i][0].split('\"')[1] not in genes: 
                genes.append(dict[i][0].split('\"')[1]) 
writer.writerow([dict[i][0].split('\"')[1],dict[i][1],dict[i][2],dict[i][3],str(dict[i][4]),tf,fam,tf_seq,cs
s,mss]) 
 
sref.close() 
tref.close() 
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I. SNPs coinciding with TFBSs 
 
Gene SNP Strand Chr Position TF TF Sequence CSS MSS 
B2M rs17235815 + 15 42789242 AIRE gtTTTTAaattggttttccaagtga 0.673 0.712 
MAP2K1 rs35534818 + 15 64465511 Pax-4 AAAAAatattgccaacatggtgaaaacccg 1 0.846 
NEO1 rs8025535 + 15 71129558 HIF1 gtatACGTGcaggc 1 0.979 
CSK rs7496625 + 15 72861395 TBX5 caccACACCtat 1 0.973 
AKAP13 rs12437885 + 15 83722873 Tal-1beta:E47 tagtaCAGATggcgtt 1 0.922 
PCSK6 rs1472303 - 15 99849029 myogenin gaccgcttggggACGGCgggcggccgggg 0.637 0.705 
AR rs34566600 + X 66678721 PLZF gtggaagcaacaTAAACtttggagtcttt 0.976 0.802 
ARMCX1 rs6621104 + X 100690370 PLZF ttgtatttttaaTAAAGatggcgttttac 1 0.819 
ARMCX3 rs2858167 + X 100764000 Hand1:E47 attgCCAGAcacactg 1 0.981 
BIRC4 rs7064224 + X 122820033 Pax CAGGCactcac 0.74 0.861 
FOXP3 rs35851078 - X 49008459 CDP CTATAcacttttgtt 0.98 0.826 
MMP14 rs1957371 + 14 22373891 Pax-5 aacctgggcgacaGGGCGagactccgtc 0.873 0.753 
HIF1A rs4902079 + 14 61230050 Pax-5 tccgagtgtggtgGTGCGtgcctgtaat 0.839 0.767 
MUC2 rs35123704 + 11 1063794 Pax CAGGAactcaa 0.857 0.847 
ILK rs2659860 + 11 6581236 AP-2 gaggccgCAGGCg 1 0.98 
ADM rs5001 + 11 10282837 Pax-5 ggggctaggactctcCTTTGccccttga 0.965 0.839 
CD44 rs7944409 + 11 35115929 Pax-5 tgcctcgtgcCGCTGagcctggcgcaga 0.919 0.744 
CD82 rs16914075 + 11 44543302 myogenin ttcagggagaaaGCCAGctttgagggctt 0.9 0.724 
GSTP1 rs4147581 + 11 67108161 Pax-3 agtttcgcCGTGAccttctgc 1 0.862 
CCND1 rs954619 + 11 69163915 CDP cacgaacaccTATCG 0.998 0.948 
BIRC2 rs5794168 + 11 101723404 RFX ggGCAACtg 1 0.988 
ATM rs3205808 + 11 107599080 GATA-X tgtgcTTATCa 1 0.991 
LOH11CR2A rs1939849 + 11 123489876 AIRE tcATCTTtatcggtttaattgtgta 0.679 0.707 
 
  Continued… 
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Gene SNP Strand Chr Position TF TF Sequence CSS MSS 
IGF2 rs1050197 - 11 2116105 MyoD ctggggCAGGTggcggct 1 0.984 
MEN1 rs650277 - 11 64334871 Pax-5 agcctgagtgacaGAGCGagactctgtc 0.973 0.819 
MMP1 rs17882592 - 11 102175154 Pax-5 cccagagtcaCGCTCagtctctttccag 0.973 0.773 
IL18 rs5744223 - 11 111541778 Pax-6 tccatctgattCTTAAaatat 0.792 0.743 
APOA1 rs2727786 - 11 116213733 Pax-5 gcggggcgggacgGAGCGgggcggcctc 0.973 0.744 
MCAM rs3923594 - 11 118693125 Sp1 cggGGCGGgg 1 0.993 
MSX1 rs13104352 + 4 4908791 WT1 gggGGAGGg 1 1 
PDGFRA rs1800812 + 4 54789386 GATA-4 AGATAgaagcca 1 0.943 
KIT rs6554199 + 4 55217245 CDP cacagagaccTTTGG 0.745 0.808 
CXCL1 rs6825295 + 4 74952346 c-Ets-1 ccttccTTCCGgactc 1 0.952 
EDNRA rs3190169 + 4 148621911 myogenin atttaggtaagtACCAAaaagtagaattg 0.929 0.731 
MAD2L1 rs2934378 - 4 121207924 FAC1 actaACAACactca 1 0.94 
EDN1 rs2854239 + 6 12396669 myogenin cagcgctggcttCCGGCtcagtgccgcct 0.687 0.759 
E2F3 rs9465729 + 6 20508517 ETF CCGCCgc 1 1 
DDR1 rs34119233 + 6 30956073 YY1 GCCATgttg 1 0.997 
TNF rs4645839 + 6 31651804 myogenin acggggctgcgtTCCAGctcacccaggga 0.829 0.716 
HLA-DQA1 rs9272454 + 6 32713503 SREBP-1 tgGGGTG 1 1 
HMGA1 rs9380423 + 6 34312660 ZF5 gaGGGCGgcctcc 0.919 0.862 
CDKN1A rs34414143 + 6 36754408 myogenin cctgggctcccaTCCCCacagcagaggag 0.597 0.71 
PPP2R5D rs6906393 + 6 43059321 CACD ccaCACCC 1 1 
VEGFA rs1005230 + 6 43844474 CDP CAATAgatctgtgtg 0.996 0.936 
GJA1 rs35296339 + 6 121796608 POU3F2 TCATGgtaat 0.783 0.855 
MAP3K4 rs9456608 + 6 161332310 Hand1:E47 ttaataaTCTGGaatt 1 0.944 
MLLT4 rs9455902 + 6 167967870 Hand1:E47 ccgtCCAGAcccagaa 1 0.937 
HLA-DRB1 rs17878475 - 6 32665458 Pax-8 tggtagggTGTGAat 0.953 0.91 
MAP3K5 rs1474988 - 6 137155946 Tax/CREB ctggaaatgCTTCAg 0.8 0.747 
 
  Continued… 
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Gene SNP Strand Chr Position TF TF Sequence CSS MSS 
PLAGL1 rs28364590 - 6 144371507 Cart-1 aacTAATGgaaattgaga 0.951 0.901 
LATS1 rs2297932 - 6 150081054 AP-2 aaCCCACgggcg 0.969 0.952 
RNASET2 rs11557915 - 6 167289645 Pax-5 ccatgcgccctgcagCCCTGcgcggggc 0.988 0.888 
SERPINF1 rs12948385 + 17 1611651 Pax-2 tgtgtaacccATGACccac 0.991 0.9 
MAP2K4 rs9892151 + 17 11864845 C/EBP gTTGCCtaatct 1 0.994 
MAP2K3 rs28365971 + 17 21128276 Hand1:E47 ctgcgggTCTGGgggt 1 0.939 
LASP1 rs3842366 + 17 34279059 Pax-2 tagttcgtacTTGACtatg 0.979 0.906 
ERBB2 rs35771148 + 17 35098000 ER gttGGTCAgggtggtcttg 1 0.952 
CSF3 rs34616965 + 17 35420873 Spz1 tgcGGAGGgtgtact 1 0.96 
GRN rs4792937 + 17 39777388 HNF3alpha taaaacAAACA 1 0.999 
ITGB3 rs11871447 + 17 42686617 1-Oct AATTTacataga 0.93 0.958 
DLX4 rs4399574 + 17 45401010 Egr-1 ccgcGGGGGcgt 0.885 0.864 
RPS6KB1 rs36013892 + 17 55324243 S8 tacattcAATTAacat 1 0.998 
MAP3K3 rs11871767 + 17 59052455 Pax-8 ccTCACGccggagct 1 0.941 
TP53 rs17882137 - 17 7533245 CDP CAATAaacctgggtc 0.996 0.835 
BRCA1 rs3092986 - 17 38531522 Pax-2 tccataactgTTGACaagt 0.979 0.854 
MPO rs34576380 - 17 53714238 Ets gaGGAAGt 1 1 
MAP3K8 rs8176941 + 10 30761201 myogenin taaattttatttTTGGTtggccgcggtgg 0.929 0.702 
PLAU rs2227554 + 10 75340118 Pax-6 cccgtTAACActtcaatagga 0.659 0.765 
SNCG rs3793899 + 10 88708741 LRF GGGGGcccc 1 1 
PTEN rs35361056 + 10 89611571 SREBP gggttCACCCta 1 0.971 
GSTO2 rs10509769 + 10 106018060 Pax-5 gctgtcggtcCGCTCcaattgtctggtt 0.973 0.874 
CXCL12 rs2839682 - 10 44202341 ZF5 ctGCGCGcggctc 1 0.86 
TUSC3 rs11545037 + 8 15442403 Hand1:E47 agagCCAGActgtcaa 1 0.94 
E2F5 rs4150842 + 8 86277150 C/EBP tTTGCAaaactt 0.997 0.997 
EBAG9 rs1892762 + 8 110620840 Hand1:E47 agggacaTCTGGcaga 1 0.936 
 
  Continued… 
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Gene SNP Strand Chr Position TF TF Sequence CSS MSS 
MYC rs3895617 + 8 128816042 myogenin catgtgtggggcTGGGCaactagctaagt 0.817 0.731 
PTP4A3 rs28549814 + 8 142496729 ZF5 ctcgggCGCCCtc 0.919 0.873 
TNFRSF10A rs20577 - 8 23138422 CP2/LBP-1c/LSF gcggccacacCCAGC 1 0.918 
PLAT rs8178669 - 8 42185902 Pax-4 ggtgtctttttgatgtaatgatttcTTTTT 1 0.831 
PTK2 rs306954 - 8 142082141 GR aAGAACacagtgttgg 1 0.872 
COMT rs9332307 + 22 18307629 Pax-4 AAAAAttagccaggcgtggtggcagatgcc 1 0.849 
MYO18B rs4369968 + 22 24467323 CACD ccaCGCCC 0.983 0.988 
LGALS1 rs4820293 + 22 36400867 GR aAGGACagggtgcaca 0.978 0.874 
ECGF1 rs28931613 - 22 49314874 Pax-3 gcatgaagCGAGAcggaggcc 0.818 0.849 
PPARG rs17029007 + 3 12304483 C/EBPdelta agtggcGCAATc 1 0.973 
MLH1 rs1800734 + 3 37009950 v-Myb tCCGTTagt 1 0.993 
ACVR2B rs506993 + 3 38470967 c-Ets-1 aattacTTCCGttatc 1 0.968 
CTNNB1 rs11564433 + 3 41215785 CDP actttaaTCAATtgc 0.93 0.92 
SEMA3B rs36018346 + 3 50278462 Spz1 gcgGGGGGgtttctg 0.998 0.968 
PRKCI rs1082975 + 3 171422206 Pax-6 atattTTCTGgttgagtttct 0.633 0.756 
PIK3CA rs7615076 + 3 180346382 myogenin caattatttaatTTTGAagtataccattt 0.746 0.708 
CDC25A rs3731483 - 3 48205120 AP-2alpha GCCCGgggc 1 1 
GSK3B rs334557 - 3 121296168 v-Myb tCCGTTcgg 1 0.939 
ATR rs35582603 - 3 143780806 PPARalpha:RXRalpha cacctgaaggaAAAAGggca 0.875 0.751 
BCHE rs3806650 - 3 167038505 CdxA aTTAATa 1 1 
TNFSF10 rs3136581 - 3 173725855 c-Ets-1(p54) gactTCCTGc 0.974 0.973 
SST rs35603672 - 3 188870742 ZF5 caGTGCGcgctgg 0.919 0.868 
MSH3 rs1643646 + 5 79984397 FAC1 acccACAAGacaaa 0.919 0.94 
CAMK4 rs34549881 + 5 110586803 PPARalpha:RXRalpha aaaaaaaaggcCAAAAgtaa 0.751 0.776 
CTNNA1 rs28365836 + 5 138116655 Sp1 gggGGCGGgg 1 1 
DAB2 rs3812039 - 5 39462084 myogenin acattgagctacCCCAAattacacagtgg 0.911 0.706 
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Gene SNP Strand Chr Position TF TF Sequence CSS MSS 
PPAP2A rs2292279 - 5 54866630 POU6F1 gaataaTTTAT 1 0.941 
CDC25C rs11567954 - 5 137695646 Pax-6 agccaatgatgCGCCAggctc 0.737 0.777 
NTRK2 rs3758317 + 9 86472435 E2F cctTGGCGcgtc 1 0.948 
CTSL rs3118869 + 9 89530683 Pax-5 tccaggtcCACTGaggcaggcacgccca 1 0.836 
PTGS1 rs10306109 + 9 124171452 Pax-3 gtttaaggTCACGctatggaa 1 0.946 
PPP2R4 rs3124501 + 9 130913459 STAT tccCAGAAgtaga 1 0.996 
CDKN2A rs3731190 - 9 21984282 Pax-6 gggctTGACGtctgatctgta 0.925 0.794 
CXADR rs211964 + 21 17807417 HIC1 gctcgcTGCCCgcgg 1 0.978 
BACH1 rs7509867 + 21 29593108 ZF5 gccgggCGCTCtc 0.919 0.871 
CBR3 rs8132243 + 21 36429035 RFX caGTTGCca 1 0.994 
COL18A1 rs12482579 + 21 45647797 Pax-5 gtgcctgtccCGCGCaggtgcccctggc 0.839 0.743 
BAGE rs2770494 - 21 10121586 VDR tcacccttttCCCCC 0.956 0.971 
BRCA2 rs9534160 + 13 31786021 AP-2 cgccgCCGGGag 0.952 0.958 
DNAJC15 rs9594861 + 13 42493917 CDP tATCGAtctg 1 0.93 
ERCC5 rs4150250 + 13 102296426 YY1 aaacATGGC 1 0.994 
LAMP1 rs9604056 + 13 112998011 MRF-2 acttaaAATACaaa 1 0.91 
GAS6 rs8181793 + 13 113545319 CACD GGGAGtgg 0.948 0.965 
MPG rs3176362 + 16 67489 ZF5 cggctgCGCACtg 0.919 0.859 
MSLN rs12597489 + 16 749162 Muscle gtgcgccacCACACagggcct 0.995 0.926 
CIITA rs12928665 + 16 10878975 CDP CCATAtccgtttgtt 1 0.839 
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Appendix II 
 
A. read_hapmap.pl 
 
This program implementing several Perl modules (e.g. Getopt::Long, WWW::Mechanize, 
HTML::Extract, URI, etc.), enabled the retrieval of SNP genotype data for each of the 379 
candidate genes per population group in both the forward and reverse strands. The 
program reads through a flat file containing all HUGO gene symbols of the candidate 
genes (one per line), then inserts them one at a time into the text query field of the 
HapMap Genome Browser tool (i.e. "Landmark or Region"). It then performs the "Search" 
action, enabling the HUGO gene symbol to be queried through the tool. On the resulting 
webpage, the script then accesses the "Configure..." button, where it selects the 
specified strand orientation (i.e. provided as a commandline option when running the 
script) and each population group one at a time, saving the text results of each selection 
to an output folder created in the working directory. 
 
#!/usr/bin/perl -w 
 
use diagnostics; 
use Getopt::Long; 
use WWW::Mechanize; 
use HTML::TableExtract; 
use URI; 
use strict; 
 
#----------HapMap homepage----------# 
my $url = "http://www.hapmap.org"; 
my $mech = WWW::Mechanize->new(); 
 
#----------Create command line options----------# 
my ($gene,$strand,$output_dir); 
 
GetOptions( 
    "strand|s=s"  => \$strand,  
    "output|o=s"  => \$output_dir, 
); 
 
#----------Open flat file containing query genes (one per line) & run through HapMap 
Genome Browser----------#   
open(MYINPUTFILE, "Candidate_Genes.txt"); 
while(<MYINPUTFILE>) { 
    my($line) = $_; 
    chomp($line); 
    $gene = $_; 
    my($processGene); 
    for my $line ($gene){ 
        processGene(); 
    } 
} 
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#----------Submit query gene & retrieve genotype data----------# 
sub processGene { 
 
#----------Create output directory----------# 
unless(-d $output_dir){system("mkdir $output_dir");} 
my $outfile="HapMap.html"; 
open(OUTFILE,">$output_dir/$outfile"); 
chomp($gene,$strand); 
 
#----------Initialize population codes----------# 
my @pop=("ASW","CEU","CHB","CHD","GIH","JPT","LWK","MEX","MKK","TSI","YRI"); 
 
#----------Download genotype data on fwd/rev strand----------# 
foreach my $k(0..$#pop){ 
 $mech->get($url); 
 
 #---------Access HapMap Genome Browser & edit relevant fields--------# 
 $mech->follow_link(text => "HapMap Genome Browser ( Phase 1, 2 & 3 - 
merged genotypes & frequencies )");  
 
 #----------Submit query gene----------#  
 $mech->set_fields(  
  name => $gene, 
  plugin => "Download SNP genotype data",  
 );  
 $mech->submit();  
 print OUTFILE $mech->content(); 
 
 my $output_page= "$gene.$pop[$k].$strand.txt"; 
 open(OUT, ">$output_dir/$output_page"); 
 $mech->set_fields(  
  "SNPGenotypeDataPhase3Dumper.pop_code" => $pop[$k],  
  "SNPGenotypeDataPhase3Dumper.strand" => $ARGV[1], 
  "SNPGenotypeDataPhase3Dumper.format" => "todisk", 
   plugin_action=> "Go", 
 );  
  $mech->click("plugin_action"); 
 
        #----------Progress status----------# 
        # print "Downloading... $pop[$k] \n"; 
  print OUT $mech->content(); 
} 
close(OUT); 
close(OUTFILE); 
@pop=(); 
} 
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B. filter_hapmap.py 
 
This program opens and reads through all text files obtained from read_hapmap.pl 
program (i.e. genotyped SNPs occurring on all 379 candidate genes among 11 
population groups on both the forward and reverse strands) and searches for SNPs 
present in any of the population groups corresponding to the SNPs that were observed to 
overlap with TFBSs in Chapter 3 (Section 3.2.5). All SNPs that were identified in any/all 
population groups and present in File 10 (Figure 3.8) were then piped to an output flat file 
from the commandline interface. 
 
#!/usr/bin/env python 
 
import csv, os 
from table_parser import * 
ref = open("SNPs_within_TFBSs.csv","rb") 
writer = csv.writer(file('SNPs_in_all_Populations.csv', 'w')) 
 
#----------Accesses folder that stores all HapMap result files----------#  
path = "/Users/kavisharamdayal/Documents/FINAL_THESIS/8.HapMap_Results" 
HapFolder = os.listdir(path) 
 
a0 = b0 = c0 = f_0 = a1 = b1 = c1 = f_1 = a2 = b2 = c2 = f_2 = a3 = b3 = c3 = f_3 = a4 = 
b4 = c4 = f_4 = a5 = b5 = c5 = f_5 = a6 = b6 = c6 = f_6 = a7 = b7 = c7 = f_7 = a8 = b8 = 
c8 = f_8 = a9 = b9 = c9 = f_9 = a10 = b10 = c10 = f_10 = "" 
f0 = f1 = f2 = f3 = f4 = f5 = f6 = f7 = f8 = f9 = f10 = snps_in_tfbs = [] 
total_fwd_count = total_rev_count = 0 
 
for line in ref: 
    ref_gene = line.strip().split(",")[0] 
    ref_snp = line.strip().split(",")[1] 
    ref_str = line.strip().split(",")[2] 
    ref_chr = line.strip().split(",")[3] 
    ref_pos = line.strip().split(",")[4] 
    ref_tf = line.strip().split(",")[5] 
    MI = line.strip().split(",")[6] 
    tf_seq = line.strip().split(",")[7] 
    CSS = line.strip().split(",")[8] 
    MSS = line.strip().split(",")[9] 
    tf_base = line.strip().split(",")[10] 
    temp = 
str(ref_gene+"|"+ref_snp+"|"+ref_str+"|"+ref_chr+"|"+ref_pos+"|"+ref_tf+"|"+MI+"|"+tf_seq
+"|"+CSS+"|"+MSS) 
    snps_in_tfbs.append(temp) 
 
def get_info(f): 
    filename = str(f).split("'")[1] 
    gene = filename.split(".")[0] 
    pop = filename.split(".")[1] 
    strand = filename.split(".")[2] 
    return gene, pop, strand 
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def get_filecontent(f): 
    temp = [] 
    for line in f: 
        if (line.startswith("rs")) and ("#" not in line): 
            snp = line.split()[0] 
            temp.append(snp) 
    return temp 
 
#----------Analyze forward strand SNPs----------# 
fwd_commons = [] 
for file in HapFolder: 
    if file.endswith("ASW.fwd.txt"): 
        f_0 = open(file,"rb") 
        f0 = get_filecontent(f_0) 
        a0,b0,c0 = get_info(f_0) 
elif file.endswith("CEU.fwd.txt"): 
        f_1 = open(file,"rb") 
        f1 = get_filecontent(f_1) 
        a1,b1,c1 = get_info(f_1) 
elif file.endswith("CHB.fwd.txt"): 
        f_2 = open(file,"rb") 
        f2 = get_filecontent(f_2) 
        a2,b2,c2 = get_info(f_2) 
elif file.endswith("CHD.fwd.txt"): 
        f_3 = open(file,"rb") 
        f3 = get_filecontent(f_3) 
        a3,b3,c3 = get_info(f_3) 
elif file.endswith("GIH.fwd.txt"): 
        f_4 = open(file,"rb") 
        f4 = get_filecontent(f_4) 
        a4,b4,c4 = get_info(f_4) 
elif file.endswith("JPT.fwd.txt"): 
        f_5 = open(file,"rb") 
        f5 = get_filecontent(f_5) 
        a5,b5,c5 = get_info(f_5) 
elif file.endswith("LWK.fwd.txt"): 
        f_6 = open(file,"rb") 
        f6 = get_filecontent(f_6) 
        a6,b6,c6 = get_info(f_6) 
elif file.endswith("MEX.fwd.txt"): 
        f_7 = open(file,"rb") 
        f7 = get_filecontent(f_7) 
        a7,b7,c7 = get_info(f_7) 
elif file.endswith("MKK.fwd.txt"): 
        f_8 = open(file,"rb") 
        f8 = get_filecontent(f_8) 
        a8,b8,c8 = get_info(f_8) 
elif file.endswith("TSI.fwd.txt"): 
        f_9 = open(file,"rb") 
        f9 = get_filecontent(f_9) 
        a9,b9,c9 = get_info(f_9) 
elif file.endswith("YRI.fwd.txt"): 
        f_10 = open(file,"rb") 
        f10 = get_filecontent(f_10) 
        a10,b10,c10 = get_info(f_10) 
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total_fwd_count += 
len(f1)+len(f2)+len(f3)+len(f4)+len(f5)+len(f6)+len(f7)+len(f8)+len(f9)+len(f10) 
 
    if (a0==a1==a2==a3==a4==a5==a6==a7==a8==a9==a10) and 
(c0==c1==c2==c3==c4==c5==c6==c7==c8==c9==c10): 
        for snp in f0: 
            if (snp in f1) or (snp in f2) or (snp in f3) or (snp in f4) or (snp in f5) or (snp in f6) or 
(snp in f7) or(snp in f8) or (snp in f9) or (snp in f10): 
                fwd_commons.append(snp) 
 
#----------Analyze reverse strand SNPs----------# 
rev_commons = [] 
for file in HapFolder: 
    if file.endswith("ASW.rev.txt"): 
        f_0 = open(file,"rb") 
        f0 = get_filecontent(f_0) 
        a0,b0,c0 = get_info(f_0) 
elif file.endswith("CEU.rev.txt"): 
        f_1 = open(file,"rb") 
        f1 = get_filecontent(f_1) 
        a1,b1,c1 = get_info(f_1) 
elif file.endswith("CHB.rev.txt"): 
        f_2 = open(file,"rb") 
        f2 = get_filecontent(f_2) 
        a2,b2,c2 = get_info(f_2) 
elif file.endswith("CHD.rev.txt"): 
        f_3 = open(file,"rb") 
        f3 = get_filecontent(f_3) 
        a3,b3,c3 = get_info(f_3) 
elif file.endswith("GIH.rev.txt"): 
        f_4 = open(file,"rb") 
        f4 = get_filecontent(f_4) 
        a4,b4,c4 = get_info(f_4) 
elif file.endswith("JPT.rev.txt"): 
        f_5 = open(file,"rb") 
        f5 = get_filecontent(f_5) 
        a5,b5,c5 = get_info(f_5) 
elif file.endswith("LWK.rev.txt"): 
        f_6 = open(file,"rb") 
        f6 = get_filecontent(f_6) 
        a6,b6,c6 = get_info(f_6) 
elif file.endswith("MEX.rev.txt"): 
        f_7 = open(file,"rb") 
        f7 = get_filecontent(f_7) 
        a7,b7,c7 = get_info(f_7) 
elif file.endswith("MKK.rev.txt"): 
        f_8 = open(file,"rb") 
        f8 = get_filecontent(f_8) 
        a8,b8,c8 = get_info(f_8) 
elif file.endswith("TSI.rev.txt"): 
        f_9 = open(file,"rb") 
        f9 = get_filecontent(f_9) 
        a9,b9,c9 = get_info(f_9) 
elif file.endswith("YRI.rev.txt"): 
        f_10 = open(file,"rb") 
        f10 = get_filecontent(f_10) 
        a10,b10,c10 = get_info(f_10) 
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    total_rev_count += 
len(f1)+len(f2)+len(f3)+len(f4)+len(f5)+len(f6)+len(f7)+len(f8)+len(f9)+len(f10) 
 
    if (a0==a1==a2==a3==a4==a5==a6==a7==a8==a9==a10) and 
(c0==c1==c2==c3==c4==c5==c6==c7==c8==c9==c10): 
        for snp in f0: 
            if (snp in f1) or (snp in f2) or (snp in f3) or (snp in f4) or (snp in f5) or (snp in f6) or 
(snp in f7) or (snp in f8) or (snp in f9) or (snp in f10): 
                rev_commons.append(snp) 
 
for i in snps_in_tfbs: 
    gene = i.split("|")[0] 
    snp = i.split("|")[1] 
    strand = i.split("|")[2] 
    chr = i.split("|")[3] 
    pos = i.split("|")[4] 
    tf = i.split("|")[5] 
    MI = i.split("|")[6] 
    tf_seq = i.split("|")[7] 
    CSS = i.split("|")[8] 
    MSS = i.split("|")[9] 
    tf_base = i.split("|")[10] 
 
if (strand == "+") and (snp in fwd_commons): 
        print gene,snp,strand,chr,pos,tf,tf_seq,CSS,MSS,tf_base 
    elif (strand == "-") and (snp in rev_commons): 
        print gene,snp,strand,chr,pos,tf,tf_seq,CSS,MSS,tf_base 
     
f_0.close() 
f_1.close() 
f_2.close() 
f_3.close() 
f_4.close() 
f_5.close() 
f_6.close() 
f_7.close() 
f_8.close() 
f_9.close() 
f_10.close() 
ref.close() 
 
#print "snps_in_tfbs",len(snps_in_tfbs) = 988 
#print "fwd_commons",len(fwd_commons) = 23852 
#print "rev_commons",len(rev_commons) = 24133 
#print "total fwd snps",total_fwd_count = 5865604 
#print "total rev snps",total_rev_count = 5878560 
 
 
 
 
